Set Analyses:
Advanced Search

Advanced Search

Search By
Section (entire)

or upload a file of gene symbols

Category   Symbol Source: HGNC EntrezGene Ensembl GeneCards RNA genes CroW21

FLT3 Gene

protein-coding   GIFtS: 71
GCID: GC13M028577

Fms-Related Tyrosine Kinase 3

  See related diseases

(According to 1HGNC, 2Entrez Gene,
3UniProtKB/Swiss-Prot, 4UniProtKB/TrEMBL, 5OMIM, 6GeneLoc, 7Ensembl, 8DME, 9miRBase, 10fRNAdb, 12H-InvDB, 13NCBI, 14NONCODE, and/or 15RNAdb)
About This Section

Fms-Related Tyrosine Kinase 31 2     FL Cytokine Receptor2 3
Fms-Like Tyrosine Kinase 32 3     EC 8
Stem Cell Tyrosine Kinase 12 3     Fetal Liver Kinase 22
CD1352 3     Growth Factor Receptor Tyrosine Kinase Type III2
FLK-22 3     Receptor-Type Tyrosine-Protein Kinase FLT32
FLK22 3     FLT-33
STK-12 3     Fetal Liver Kinase-23
STK12 3     EC 2.7.108
CD135 Antigen2 3     

External Ids:    HGNC: 37651   Entrez Gene: 23222   Ensembl: ENSG000001220257   OMIM: 1363515   UniProtKB: P368883   

Export aliases for FLT3 gene to outside databases

Previous GC identifers: GC13M026557 GC13M022557 GC13M027507 GC13M026375 GC13M027475 GC13M009398

(According to Entrez Gene, Tocris Bioscience, Wikipedia's Gene Wiki, PharmGKB,
UniProtKB/Swiss-Prot, and/or UniProtKB/TrEMBL)
About This Section

Entrez Gene summary for FLT3 Gene:
This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an
extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic
kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the
fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma
membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently
phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis,
proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the
constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.
(provided by RefSeq, Jul 2008)

GeneCards Summary for FLT3 Gene: 
FLT3 (fms-related tyrosine kinase 3) is a protein-coding gene. Diseases associated with FLT3 include tetraploidy, and acute lymphoblastic leukemia, and among its related super-pathways are STAT3 Pathway and Ras Pathway. GO annotations related to this gene include cytokine receptor activity and protein homodimerization activity. An important paralog of this gene is FLT4.

UniProtKB/Swiss-Prot: FLT3_HUMAN, P36888
Function: Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates
differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes
phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS
signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes
phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type
FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity
promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways

summary for FLT3 Gene:
FMS-like receptor tyrosine kinase-3 (FLT3) is a member of the class III RTK (receptor tyrosine kinase)
family and is expressed primarily in hematopoietic progenitor cells. The expression within these cells
demonstrates that FLT3 has an important role in the pathogenesis of AML (acute myelogenous leukemia), under
which conditions wild type receptors are overexpressed or mutated forms of the receptor are present.
Inhibitors of both mutated and wild type receptors are therefore of interest in a therapeutic context.

Gene Wiki entry for FLT3 (CD135) Gene

(According to GeneLoc and/or HGNC, and/or
Entrez Gene (NCBI build 37),
and/or miRBase,
Genomic Views according to UCSC (hg19) and Ensembl (release 73), Regulatory elements and Epigenetics data according to QIAGEN, SABiosciences, and/or SwitchGear Genomics)
About This Section
RefSeq DNA sequence:
NC_000013.10  NT_024524.14  NC_018924.2  
Regulatory elements:
   SABiosciences Regulatory transcription factor binding sites in the FLT3 gene promoter:
         STAT5B   Pax-5   AP-1   ATF-2   GATA-2   C/EBPalpha   STAT3   c-Jun   NF-kappaB1   Hlf   
         Other transcription factors

SwitchGear Promoter luciferase reporter plasmidFLT3 promoter sequence
   Search SABiosciences Chromatin IP Primers for FLT3

QIAGEN PyroMark CpG Assay predesigned Pyrosequencing DNA Methylation assays in human, mouse, rat FLT3

Genomic Location:
Genomic View: UCSC Golden Path with GeneCards custom track

Entrez Gene cytogenetic band: 13q12   Ensembl cytogenetic band:  13q12.2   HGNC cytogenetic band: 13q12

FLT3 Gene in genomic location: bands according to Ensembl, locations according to (and/or Entrez Gene and/or Ensembl if different)
FLT3 gene location

GeneLoc information about chromosome 13         GeneLoc Exon Structure

GeneLoc location for GC13M028577:  view genomic region     (about GC identifiers)

28,577,411 bp from pter      End:
28,674,729 bp from pter
97,319 bases      Orientation:
minus strand

(According to UniProtKB, HORDE, neXtProt, Ensembl, and/or Reactome, Modification sites according to PhosphoSitePlus, Specific Peptides from DME, Protein expression images according to data from SPIRE 1MOPED, 2PaxDb, and 3MAXQB RefSeq according to NCBI, PDB rendering according to OCA and/or Proteopedia, Recombinant Proteins from EMD Millipore, R&D Systems, GenScript, Enzo Life Sciences, OriGene, Novus Biologicals, Sino Biological, ProSpec, and/or Cloud-Clone Corp.,
Biochemical Assays by EMD Millipore, R&D Systems, OriGene, GenScript, Cell Signaling Technology, Enzo Life Sciences, and/or Cloud-Clone Corp., Ontologies according to Gene Ontology Consortium 01 Oct 2013 and Entrez Gene, Antibodies by EMD Millipore, R&D Systems, GenScript, Cell Signaling Technology, OriGene, Novus Biologicals, Thermo Fisher Scientific, LSBio, Abcam, and/or Cloud-Clone Corp.)
About This Section

UniProtKB/Swiss-Prot: FLT3_HUMAN, P36888 (See protein sequence)
Recommended Name: Receptor-type tyrosine-protein kinase FLT3 precursor  
Size: 993 amino acids; 112903 Da
Subunit: Monomer in the absence of bound FLT3LG. Homodimer in the presence of bound FLT3LG. Interacts with FIZ1
following ligand activation (By similarity). Interacts with FES, FER, LYN, FGR, HCK, SRC and GRB2. Interacts with
Subcellular location: Membrane; Single-pass type I membrane protein. Endoplasmic reticulum lumen.
Note=Constitutively activated mutant forms with internal tandem duplications are less efficiently transported to
the cell surface and a significant proportion is retained in an immature form in the endoplasmic reticulum lumen.
The activated kinase is rapidly targeted for degradation
Miscellaneous: Can be used as diagnostic tool to establish the exact cause of acute myeloid leukemia, and to
determine the optimal therapy
3 PDB 3D structures from and Proteopedia for FLT3:
1RJB (3D)        3QS7 (3D)        3QS9 (3D)    
Secondary accessions: A0AVG9 B7ZLT7 B7ZLT8 F5H0A0 Q13414
Alternative splicing: 2 isoforms:  P36888-1   P36888-2   

Explore the universe of human proteins at neXtProt for FLT3: NX_P36888

Explore proteomics data for FLT3 at MOPED 

Post-translational modifications:

  • UniProtKB: N-glycosylated, contains complex N-glycans with sialic acid
  • UniProtKB: Autophosphorylated on several tyrosine residues in response to FLT3LG binding. FLT3LG binding also increases
    phosphorylation of mutant kinases that are constitutively activated. Dephosphorylated by PTPRJ/DEP-1, PTPN1,
    PTPN6/SHP-1, and to a lesser degree by PTPN12. Dephosphorylation is important for export from the endoplasmic
    reticulum and location at the cell membrane
  • UniProtKB: Rapidly ubiquitinated by UBE2L6 and the E3 ubiquitin-protein ligase SIAH1 after autophosphorylation, leading to
    its proteasomal degradation
  • View modification sites using PhosphoSitePlus
  • View neXtProt modification sites for NX_P36888

  • 4/13 DME Specific Peptides for FLT3 (P36888) (see all 13)

    FLT3 Protein expression data from MOPED1, PaxDb2 and MAXQB3 :    About this image 

    FLT3 Protein Expression
    REFSEQ proteins: NP_004110.2  
    ENSEMBL proteins: 
     ENSP00000241453   ENSP00000370374   ENSP00000370369   ENSP00000438139  

    Human Recombinant Protein Products for FLT3: 
    EMD Millipore Purified and/or Recombinant FLT3 Protein
    R&D Systems Recombinant & Natural Proteins for FLT3 (Flt-3/Flk-2)
    Enzo Life Sciences proteins for FLT3
    OriGene Purified Protein for FLT3
    OriGene Protein Over-expression Lysate for FLT3
    OriGene MassSpec for FLT3 
    OriGene Custom Protein Services for FLT3
    GenScript Purified and Recombinant Proteins for FLT3
    Novus Biologicals FLT3 Proteins
    Novus Biologicals FLT3 Lysate
    Sino Biological Recombinant Protein for FLT3
    Sino Biological Cell Lysate for FLT3 
    Browse ProSpec Recombinant Proteins
    Browse Proteins at Cloud-Clone Corp. 

    Gene Ontology (GO): 5 cellular component terms (GO ID links to tree view):    About this table

    GO IDQualified GO termEvidencePubMed IDs
    GO:0005788endoplasmic reticulum lumen IEA--
    GO:0005887integral to plasma membrane TAS8394751
    GO:0009986cell surface IEA--
    GO:0016020membrane ----
    GO:0016021integral to membrane ----

    FLT3 for ontologies           About GeneDecksing

    FLT3 Antibody Products: 
    EMD Millipore Mono- and Polyclonal Antibodies for the study of FLT3
    R&D Systems Antibodies for FLT3 (Flt-3/Flk-2)
    Cell Signaling Technology (CST) Antibodies for FLT3 
    OriGene Antibodies for FLT3
    OriGene Custom Antibody Services for FLT3
    GenScript Custom Superior Antibodies Services for FLT3
    Novus Biologicals FLT3 Antibodies
    Abcam antibodies for FLT3
    Browse Antibodies at Cloud-Clone Corp. 
    ThermoFisher Antibody for FLT3
    LSBio Antibodies in human, mouse, rat for FLT3 

    Assay Products for FLT3: 
    Browse Kits and Assays available from EMD Millipore
    OriGene Custom Assay Services for FLT3
    R&D Systems ELISAs for FLT3 (Flt-3/Flk-2)         (see all)
    GenScript FLT3-Activity-based Kinase Assay for Compound Screening
    Cell Signaling Technology (CST) Sandwich ELISA Kits for FLT3
    Browse Enzo Life Sciences for kits & assays
    Browse ELISAs at Cloud-Clone Corp. 
    Browse CLIAs at Cloud-Clone Corp.

    (According to HGNC, IUPHAR, InterPro, ProtoNet, UniProtKB, and/or BLOCKS, Sets of similar genes according to GeneDecks)
    About This Section
    HGNC Gene Families: 
    CD: CD molecules
    IGD: Immunoglobulin superfamily / Immunoglobulin-like domain containing

    IUPHAR Guide to PHARMACOLOGY protein family classification: fms-related tyrosine kinase 3 
    PDGF (platelet-derived growth factor) receptor family
    PDGF (platelet-derived growth factor) receptor family

    5/12 InterPro protein domains (see all 12):
     IPR017441 Protein_kinase_ATP_BS
     IPR011009 Kinase-like_dom
     IPR013783 Ig-like_fold
     IPR000719 Prot_kinase_cat_dom
     IPR001824 Tyr_kinase_rcpt_3_CS

    Graphical View of Domain Structure for InterPro Entry P36888

    ProtoNet protein and cluster: P36888

    2 Blocks protein domains:
    IPB003599 Immunoglobulin subtype
    IPB008266 Tyrosine protein kinase

    UniProtKB/Swiss-Prot: FLT3_HUMAN, P36888
    Domain: The juxtamembrane autoregulatory region is important for normal regulation of the kinase activity and for
    maintaining the kinase in an inactive state in the absence of bound ligand. Upon tyrosine phosphorylation, it
    mediates interaction with the SH2 domains of numerous signaling partners. In-frame internal tandem duplications
    (ITDs) result in constitutive activation of the kinase. The activity of the mutant kinase can be stimulated
    further by FLT3LG binding
    Similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily
    Similarity: Contains 1 Ig-like C2-type (immunoglobulin-like) domain
    Similarity: Contains 1 protein kinase domain

    FLT3 for domains           About GeneDecksing

    (According to 1UniProtKB, Genatlas, LifeMap Discovery™, IUBMB, and/or 2DME, Human phenotypes from GenomeRNAi, Animal models from MGI Mar 06 2013, inGenious Targeting Laboratory, genOway,
    bound targets from SABiosciences, miRNA Gene Targets from miRTarBase, shRNA from OriGene, RNAi from EMD Millipore, siRNAs from OriGene, QIAGEN, microRNA from QIAGEN, Gene Editing from DNA2.0, Sirion Biotech, Clones from EMD Millipore, OriGene, SwitchGear Genomics, GenScript, Sino Biological, DNA2.0, Vector BioLabs, and Sirion Biotech, Cell Lines from GenScript, LifeMap BioReagents, In Situ Hybridization Assays from Advanced Cell Diagnostics, Ontologies according to Gene Ontology Consortium 01 Oct 2013 via Entrez Gene.)
    About This Section

    Molecular Function:

         UniProtKB/Swiss-Prot Summary: FLT3_HUMAN, P36888
    Function: Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates
    differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes
    phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS
    signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes
    phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type
    FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity
    promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways
    Catalytic activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate
    Enzyme regulation: Present in an inactive conformation in the absence of bound ligand. FLT3LG binding leads to
    dimerization and activation by autophosphorylation

         Genatlas biochemistry entry for FLT3:
    fms-related receptor tyrosine kinase 3,expressed on endothelial cell,duplicated in childhood acute myeloid
    leukemia with poor prognosis and acute lymphoblastic leukemia but not in myelodysplastic syndrome

         Enzyme Numbers (IUBMB): EC 2 EC 2.7.102

         Gene Ontology (GO): 5/10 molecular function terms (GO ID links to tree view) (see all 10):    About this table

    GO IDQualified GO termEvidencePubMed IDs
    GO:0004672protein kinase activity ----
    GO:0004713protein tyrosine kinase activity ----
    GO:0004714transmembrane receptor protein tyrosine kinase activity TAS19549778
    GO:0004896cytokine receptor activity ISS--
    GO:0005021vascular endothelial growth factor-activated receptor activity TAS8394751
    FLT3 for ontologies           About GeneDecksing

         2 GenomeRNAi human phenotypes for FLT3:
     Decreased substrate adherent c  Decreased viability 

         7 MGI mutant phenotypes (inferred from 4 alleles(MGI details for Flt3):
     cellular  growth/size  hematopoietic system  homeostasis/metabolism  immune system 
     mortality/aging  tumorigenesis 

    FLT3 for phenotypes           About GeneDecksing

    Animal Models:
         MGI mouse knock-out Flt3tm1Irl for FLT3

       inGenious Targeting Laboratory - Custom generated mouse model solutions for FLT3 
       inGenious Targeting Laboratory - Custom generated inducible mouse model solutions for FLT3

       genOway customized KO model: permanent, tissue-specific or time-controlled inactivation for FLT3 
       genOway customized Knockin model: humanization, point mutation, expression monitoring, etc. for FLT3 

    QIAGEN Custom miScript Target Protector blocks miRNA-binding site of human, mouse, rat FLT3
    8/33 QIAGEN miScript miRNA Assays for microRNAs that regulate FLT3 (see all 33):
    hsa-miR-3194-5p hsa-miR-15a hsa-miR-1245 hsa-miR-139-5p hsa-miR-3074-3p hsa-miR-570 hsa-miR-3142 hsa-miR-424
    SwitchGear 3'UTR luciferase reporter plasmidFLT3 3' UTR sequence
    Inhib. RNA
    Browse for Gene Knock-down Tools from EMD Millipore
    OriGene RNAi products in human, mouse, rat for FLT3
    QIAGEN FlexiTube/FlexiPlate siRNA for gene silencing in human, mouse, rat FLT3

    Gene Editing
    DNA2.0 Custom Protein Engineering Service for FLT3
    Sirion Biotech Customized adenovirus for overexpression of FLT3

    Browse Clones for the Expression of Recombinant Proteins Available from EMD Millipore
    OriGene clones in human, mouse for FLT3 (see all 9)
    OriGene ORF clones in mouse, rat for FLT3
    OriGene custom cloning services - gene synthesis, subcloning, mutagenesis, variant library, vector shuttling
    GenScript: all cDNA clones in your preferred vector: FLT3 (NM_004119)
    Sino Biological Human cDNA Clone for FLT3
    DNA2.0 Custom Codon Optimized Gene Synthesis Service for FLT3
    Vector BioLabs ready-to-use adenovirus/AAV for human, mouse, rat FLT3
    Sirion Biotech Customized lentivirus for stable overexpression of FLT3 
                         Customized lentivirus expression plasmids for stable overexpression of FLT3 

    Cell Line
    GenScript Custom overexpressing Cell Line Services for FLT3
    Search LifeMap BioReagents cell lines for FLT3
    In Situ Assay

    Advanced Cell Diagnostics RNAscope RNA in situ hybridization assays for FLT3

    (Pathways according to EMD Millipore, R&D Systems, Cell Signaling Technology, KEGG, PharmGKB, BioSystems, Sino Biological, Reactome, Tocris Bioscience, GeneGo (Thomson Reuters), QIAGEN, and/or UniProtKB, Sets of similar genes according to GeneDecks, Interaction Networks according to SABiosciences, and/or STRING, Interactions according to 1UniProtKB, 2MINT, 3I2D, and/or 4STRING, with links to IntAct and Ensembl, Ontologies according to Gene Ontology Consortium 01 Oct 2013 via Entrez Gene).
    About This Section

    SuperPaths for FLT3 About   (see all 17)                                                                                              See pathways by source

    SuperPathContained pathways About
    1PEDF Induced Signaling
    Endothelin-1 Signaling Pathway0.46
    Cytokine-cytokine receptor interaction0.43
    2GPCR Pathway
    Ras Pathway0.73
    Breast Cancer Regulation by Stathmin10.58
    Paxillin Interactions0.73
    NFAT in Immune Response0.58
    GPCR Pathway0.62
    Estrogen Pathway0.55
    Pancreatic Adenocarcinoma0.59
    P2Y Receptor Signaling0.38
    3Rho Family GTPases
    Rho Family GTPases0.61
    Molecular Mechanisms of Cancer0.51
    ERK Signaling0.61
    ILK Signaling0.49
    MAPK Signaling0.58
    4Nanog in Mammalian ESC Pluripotency
    Nanog in Mammalian ESC Pluripotency0.61
    14-3-3 Induced Intracellular Signaling0.59
    GSK3 Signaling0.61
    eNOS Signaling0.48
    5Actin Nucleation by ARP-WASP Complex
    Actin Nucleation by ARP-WASP Complex0.66
    CDC42 Pathway0.41
    Actin Nucleation and Branching0.66

    Pathways by source                                                                                                                                                                 See SuperPaths
    Show all pathways

    1 EMD Millipore Pathway for FLT3
        Development Flt3 signaling

    5/29 Downloadable PowerPoint Slides of QIAGEN Pathway Central Maps for FLT3 (see all 29)
        FLT3 Signaling
    MAPK Signaling
    Paxillin Interactions
    Endothelin-1 Signaling Pathway
    Molecular Mechanisms of Cancer

    1 Cell Signaling Technology (CST) Pathway for FLT3
        Tyrosine Kinases / Adaptors

    1 GeneGo (Thomson Reuters) Pathway for FLT3
        Development Flt3 signaling

    1 PharmGKB Pathway for FLT3
        Sorafenib Pharmacodynamics

    5         Kegg Pathways  (Kegg details for FLT3):
        Cytokine-cytokine receptor interaction
    Hematopoietic cell lineage
    Pathways in cancer
    Transcriptional misregulation in cancer
    Acute myeloid leukemia

    FLT3 for pathways           About GeneDecksing


        SABiosciences Gene Network CentralTM Interacting Genes and Proteins Network for FLT3

    STRING Interaction Network Preview (showing 5 interactants - click image to see 25)

    5/32 Interacting proteins for FLT3 (P368881, 2, 3 ENSP000002414534) via UniProtKB, MINT, STRING, and/or I2D (see all 32)
    InteractantInteraction Details
    GeneCardExternal ID(s)
    PIK3R1P279862, 3, ENSP000002743354MINT-7103574 MINT-7103585 I2D: score=2 STRING: ENSP00000274335
    PTPN11Q061242, 3, ENSP000003409444MINT-8030324 MINT-8030340 I2D: score=1 STRING: ENSP00000340944
    IKBKGQ9Y6K91, 3, ENSP000003586224EBI-3946257,EBI-81279 I2D: score=1 STRING: ENSP00000358622
    SOCS1O155243, ENSP000003294184I2D: score=4 STRING: ENSP00000329418
    INPP5DQ928353, ENSP000003525754I2D: score=3 STRING: ENSP00000352575
    About this table

    Gene Ontology (GO): 5/27 biological process terms (GO ID links to tree view) (see all 27):    About this table

    GO IDQualified GO termEvidencePubMed IDs
    GO:0001776leukocyte homeostasis ISS--
    GO:0002318myeloid progenitor cell differentiation ISS--
    GO:0002320lymphoid progenitor cell differentiation ----
    GO:0002328pro-B cell differentiation ISS--
    GO:0002572pro-T cell differentiation IEA--

    FLT3 for ontologies           About GeneDecksing

    (Chemical Compounds according to UniProtKB, Enzo Life Sciences, EMD Millipore, Tocris Bioscience HMDB, BitterDB, and/or Novoseek, Ligands according to IUPHAR, and Drugs according to DrugBank, Enzo Life Sciences, and/or PharmGKB, with drugs/clinical trials/news search links to CenterWatch)
    About This Section

    FLT3 for compounds           About GeneDecksing

    EMD Millipore small molecules for FLT3:
    Small Molecule - inhibitor
    Browse drugs & compounds from Enzo Life Sciences

    Compounds for FLT3 available from Tocris Bioscience    About this table
    CompoundAction CAS #
    TCS 359Potent FLT3 inhibitor[301305-73-7]
    5'-FluoroindirubinoximeFLT3 inhibitor; displays antiproliferative activity[861214-33-7]

    2 HMDB Compounds for FLT3    About this table
    CompoundSynonyms CAS #PubMed Ids
    ADPadenosindiphosphorsaeure (see all 8)58-64-0--
    Adenosine triphosphate5'-(tetrahydrogen triphosphate) Adenosine (see all 24)56-65-5--

    3 DrugBank Compounds for FLT3    About this table
    CompoundSynonyms CAS #TypeActionsPubMed Ids
    SunitinibSU011248 (see all 2)557795-19-4targetmultitarget14654525 12531805 15304385 15180525 11752352 14753710
    Sorafenib-- 284461-73-0targetantagonist17229632 17205056
    Ponatinib -- 943319-70-8targetinhibitor23430109

    1 IUPHAR Ligand for FLT3 (fms-related tyrosine kinase 3)    About this table 
    LigandTypeActionAffinityPubmed IDs
    Fms-related tyrosine kinase 3 ligand

    10/40 Novoseek inferred chemical compound relationships for FLT3 gene (see all 40)    About this table
    Compound   -log (P-Val)   Hits   PubMed IDs for Articles with Shared Sentences (# sentences)
    pkc 412 91.7 85 17330105 (5), 18071308 (5), 15956279 (4), 15150124 (4) (see all 27)
    lestaurtinib 88.1 22 16868253 (4), 16857985 (2), 20141349 (2), 18341639 (2) (see all 7)
    tyrosine 85.3 556 17851558 (7), 15345597 (4), 9737679 (3), 14726387 (3) (see all 99)
    tandutinib 84.9 24 16902153 (4), 15256420 (3), 15242881 (3), 19625780 (3) (see all 6)
    ag-1296 80.8 21 11455967 (7), 12357354 (2), 17050201 (2), 18509353 (2) (see all 6)
    sunitinib 74.2 28 17889720 (4), 17041096 (3), 17591828 (1), 18192256 (1) (see all 20)
    daniplestim 67.8 1 10781904 (1)
    imatinib 67.8 30 18797870 (3), 14976243 (2), 15180525 (2), 11290609 (1) (see all 13)
    sorafenib 67.5 37 17229632 (6), 18230792 (4), 17889720 (4), 17205056 (2) (see all 20)
    su5416 62.1 11 15158089 (5), 12351406 (2), 17169805 (1), 12649163 (1) (see all 5)

    Search CenterWatch for drugs/clinical trials and news about FLT3

    (Secondary structures according to fRNAdb,
    GenBank/EMBL/DDBJ Accessions according to
    Unigene (Build 236 Homo sapiens; Apr 25 2013) or GenBank,
    RefSeq according to Entrez Gene,
    DOTS (version 10), and/or AceView, transcript ids from Ensembl with links to UCSC,
    Conferences by KenesGroup, exon structure from GeneLoc, alternative splicing isoforms according to ASD and/or ECgene,
    RNAi Products from EMD Millipore,
    siRNAs from OriGene, QIAGEN, shRNA from OriGene, microRNA from QIAGEN,
    Tagged/untagged cDNA clones from OriGene, SwitchGear Genomics, GenScript, DNA2.0, Vector BioLabs, Sirion Biotech, Primers from OriGene, SABiosciences, and/or QIAGEN )
    About This Section

    REFSEQ mRNAs for FLT3 gene: 

    Unigene Cluster for FLT3:

    Fms-related tyrosine kinase 3
    Hs.507590  [show with all ESTs]
    Unigene Representative Sequence: NM_004119
    5 Ensembl transcripts including schematic representations, and UCSC links where relevant:
    ENST00000241453(uc001urw.3 uc010aao.3 uc010tdn.2) ENST00000380987
    ENST00000469894 ENST00000380982 ENST00000537084
    QIAGEN Custom miScript Target Protector blocks miRNA-binding site of human, mouse, rat FLT3
    8/33 QIAGEN miScript miRNA Assays for microRNAs that regulate FLT3 (see all 33):
    hsa-miR-3194-5p hsa-miR-15a hsa-miR-1245 hsa-miR-139-5p hsa-miR-3074-3p hsa-miR-570 hsa-miR-3142 hsa-miR-424
    SwitchGear 3'UTR luciferase reporter plasmidFLT3 3' UTR sequence
    Inhib. RNA
    Browse for Gene Knock-down Tools from EMD Millipore
    OriGene RNAi products in human, mouse, rat for FLT3
    QIAGEN FlexiTube/FlexiPlate siRNA for gene silencing in human, mouse, rat FLT3
    OriGene clones in human, mouse for FLT3 (see all 9)
    OriGene ORF clones in mouse, rat for FLT3
    OriGene custom cloning services - gene synthesis, subcloning, mutagenesis, variant library, vector shuttling
    GenScript: all cDNA clones in your preferred vector: FLT3 (NM_004119)
    DNA2.0 Custom Codon Optimized Gene Synthesis Service for FLT3
    Vector BioLabs ready-to-use adenovirus/AAV for human, mouse, rat FLT3
    Sirion Biotech Customized lentivirus for stable overexpression of FLT3 
                         Customized lentivirus expression plasmids for stable overexpression of FLT3 
    OriGene qSTAR qPCR primer pairs in human, mouse for FLT3
    SABiosciences RT2 qPCR Primer Assay in human, mouse, rat FLT3
      QIAGEN QuantiTect SYBR Green Assays in human, mouse, rat FLT3
      QIAGEN QuantiFast Probe-based Assays in human, mouse, rat FLT3

    Additional mRNA sequence: 

    BC126350.1 BC144039.1 BC144040.1 L36162.1 U02687.1 Z26652.1 

    4 DOTS entries:

    DT.120782229  DT.104253  DT.75174632  DT.91675080 

    17 AceView cDNA sequences:

    BU681356 BF589957 BC036028 BX279530 AW772610 U02687 AW059681 NM_004119 
    AV713950 Z26652 L36162 BI461248 AW057705 AI150354 BF170536 BF176247 

    GeneLoc Exon Structure

    (RNA expression data according to H-InvDB, NONCODE, miRBase, and RNAdb, Expression images according to data from BioGPS, Illumina Human BodyMap, and CGAP SAGE, Sets of similar genes according to GeneDecks, in vivo and in vitro expression data from LifeMap Discovery™, plus additional links to Genevestigator, and/or SOURCE, and/or BioGPS, and/or UniProtKB,
    PCR Arrays from SABiosciences, Primers from OriGene, SABiosciences, and/or QIAGEN, In Situ Hybridization Assays from Advanced Cell Diagnostics)
    About This Section

    FLT3 expression in normal human tissues (normalized intensities)      FLT3 embryonic expression: see
    See probesets specificity/sensitivity at GeneAnnot
    About this imageBioGPS <intensity>2/3
    FLT3 Expression
    About this image

    FLT3 expression in embryonic tissues and stem cells    About this table
    Data from LifeMap, the Embryonic Development and Stem Cells Database 
     5/5 selected tissues (see all 5) fully expand
     Blood (Hematopoietic System)    fully expand to see all 17 entries
             Common Lymphoid Progenitor Cells Hematopoietic Bone Marrow
             Bone Marrow CD133+ Cells   
             stem cells (umbilical cord cd34+)   
     Umbilical Cord (Extraembryonic Tissues)
             stem cells (umbilical cord cd34+)   
     Bone (Muscoskeletal System)
             BONE MARROW   
     Spinal Cord (Nervous System)
             motor neurons   
     Brain (Nervous System)

    See FLT3 Protein Expression from SPIRE MOPED and PaxDB
    Genevestigator expression for FLT3

    SOURCE GeneReport for Unigene cluster: Hs.507590

    UniProtKB/Swiss-Prot: FLT3_HUMAN, P36888
    Tissue specificity: Detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in
    granulocyte/macrophage progenitor cells (at protein level). Detected in bone marrow, liver, thymus, spleen and
    lymph node, and at low levels in kidney and pancreas. Highly expressed in T-cell leukemia

        SABiosciences Expression via Pathway-Focused PCR Arrays including FLT3: 
              Antigen Presenting Cells in human mouse rat
              Lymphoma in human mouse rat
              T-cell & B-cell Activation in human mouse rat

    OriGene qSTAR qPCR primer pairs in human, mouse for FLT3
    SABiosciences RT2 qPCR Primer Assay in human, mouse, rat FLT3
    QIAGEN QuantiTect SYBR Green Assays in human, mouse, rat FLT3
    QIAGEN QuantiFast Probe-based Assays in human, mouse, rat FLT3
    In Situ
    Assay Products:

    Advanced Cell Diagnostics RNAscope RNA in situ hybridization assays for FLT3

    (Orthologs according to 1,2HomoloGene (2older version, for species not in 1newer version), 3euGenes, 4SGD , 5MGI Mar 06 2013, with possible further links to Flybase and/or WormBase, and/or 6Ensembl pan taxonomic compara , Gene Trees according to Ensembl and TreeFam)
    About This Section

    This gene was present in the common ancestor of animals.

    Orthologs for FLT3 gene from 5/11 species (see all 11)    About this table
    Organism Taxonomic
    Gene Description Human
    (Mus musculus)
    Mammalia Flt31 , 5 FMS-like tyrosine kinase 31, 5 83.15(n)1
      5 (86.88 cM)5
    142551  NM_010229.21  NP_034359.21 
    (Gallus gallus)
    Aves LOC1008584221 receptor-type tyrosine-protein kinase FLT3-like 65.05(n)
      100858422  XM_003640612.1  XP_003640660.1 
    (Anolis carolinensis)
    Reptilia FLT36
    fms-related tyrosine kinase 3
    1 ↔ 1
    (Danio rerio)
    Actinopterygii LOC5667081 FL cytokine receptor-like 56.82(n)
      566708  XM_001921725.1  XP_001921760.1 
    fruit fly
    (Drosophila melanogaster)
    Insecta Cad96Ca6
    PDGF- and VEGF-receptor related
    many ↔ many
    many ↔ many

    ENSEMBL Gene Tree for FLT3 (if available)
    TreeFam Gene Tree for FLT3 (if available)

    (Paralogs according to 1HomoloGene,
    2Ensembl, and 3SIMAP, Pseudogenes according to Build 68)
    About This Section
    Paralogs for FLT3 gene
    KDR2  FGFR12  FGFR22  FLT12  
    16 SIMAP similar genes for FLT3 using alignment to 3 protein entries:     FLT3_HUMAN (see all proteins):
    STK-1    RET    NIN/PDGFRB fusion    ABL1    KIT    FES
    CSF1R    FGR    urf-ret    EPHA2    DKFZp686M05208    CDK4
    FGFR2    tec    PDGFRA    TIE1

    FLT3 for paralogs           About GeneDecksing

    (SNPs/Variants according to the 1NCBI SNP Database, 2Ensembl, 3PupaSUITE, 4UniProtKB, and DNA2.0, Linkage Disequilibrium by HapMap, Structural Variations(CNVs/InDels/Inversions) from the Database of Genomic Variants, Mutations from the Human Gene Mutation Database (HGMD) and the Locus Specific Mutation Databases (LSDB), Blood group antigen gene mutations by BGMUT, Resequencing Primers from QIAGEN, Cancer Mutation PCR Arrays and Assays and Copy Number PCR Arrays from SABiosciences)
    About This Section

    10/2552 SNPs in FLT3 are shown (see all 2552)    About this table     
    Genomic DataTranscription Related DataAllele Frequencies
    SNP IDValidClinical
    Chr 13 posSequence#AA
    Acute lymphoblastic leukemia patients4--see VAR_0656832 D Y mis40--------
    Acute lymphoblastic leukemia patients4--see VAR_0656822 D V mis40--------
    Acute lymphoblastic leukemia patients4--see VAR_0656842 I M mis40--------
    Acute lymphoblastic leukemia patients4--see VAR_0656802 D H mis40--------
    Acute lymphoblastic leukemia patients4--see VAR_0656812 D N mis40--------
    Acute lymphoblastic leukemia patients4--see VAR_0656792 D E mis40--------
    Cother19547186(-) TCGAGA/TTATCA 2 D V mis10--------
    Cother19547187(-) CTCGAA/C/G/
    4 N H D Y mis10--------
    ----see VAR_0541492 V M mis40--------
    --9531466(+) GTTCCA/GGATCC 1 -- ds50010--------

    HapMap Linkage Disequilibrium report for FLT3 (28577411 - 28674729 bp)

    Structural Variations
         Database of Genomic Variants (DGV) 8 variations for FLT3:    About this table     
    Variant IDTypeSubtypePubMed ID
    esv2674990CNV Deletion23128226
    esv2677792CNV Deletion23128226
    esv1336289CNV Insertion17803354
    nsv973CNV Insertion18451855
    esv269085CNV Insertion20981092
    esv275421CNV Loss21479260
    esv34052CNV Loss18971310
    nsv826599CNV Loss20364138

    Human Gene Mutation Database (HGMD): FLT3
    5/20 SABiosciences Cancer Mutation PCR Assays for FLT3 (see all 20):
    Cosmic IdAA Change
    5/9 SABiosciences Cancer Mutation PCR Arrays containing FLT3 (see all 9):
    Hematopoietic Neoplasms
    FLT3 Pathway
    Cancer Comprehensive Panel 384HT
    Oncogene Panel 384HT
    Receptor Tyrosine Kinase (RTK) (Panel I)
    SeqTarget long-range PCR primers for resequencing FLT3
    DNA2.0 Custom Variant and Variant Library Synthesis for FLT3

    (in which this Gene is Involved, According to MalaCards, OMIM, UniProtKB, the University of Copenhagen DISEASES database, Conferences by KenesGroup, Novoseek, Genatlas, GeneTests, GAD, HuGE Navigator, and/or TGDB.)
    About This Section
    OMIM gene information: 136351   
    OMIM disorders: 601626  
    UniProtKB/Swiss-Prot: FLT3_HUMAN, P36888
  • Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of acute leukemia, a cancer of the white blood
    cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors
    at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other
    tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils,
    eosinophils and monocytes. Note=The gene represented in this entry may be involved in disease pathogenesis.
    Somatic mutations that lead to constitutive activation of FLT3 are frequent in AML patients. These mutations fall
    into two classes, the most common being in-frame internal tandem duplications of variable length in the
    juxtamembrane region that disrupt the normal regulation of the kinase activity. Likewise, point mutations in the
    activation loop of the kinase domain can result in a constitutively activated kinase

  • 20/54 diseases for FLT3 (see all 54):    About MalaCards
    tetraploidy    acute lymphoblastic leukemia    lymphoblastic leukemia    myeloid sarcoma
    bone marrow cancer    chronic myeloproliferative disease    myeloid leukemia    chronic myelomonocytic leukemia
    acute myeloid leukemia    acute promyelocytic leukemia    juvenile myelomonocytic leukemia    osteoporotic fracture
    myelofibrosis    stem cell leukemia    myelodysplastic syndromes    acute leukemia
    refractory anemia    polycythemia vera    gastrointestinal stromal tumor    polycythemia

    2 diseases from the University of Copenhagen DISEASES database for FLT3:
    Leukemia     Bone marrow cancer

    FLT3 for disorders           About GeneDecksing

    10/73 Novoseek inferred disease relationships for FLT3 gene (see all 73)    About this table

    Disease   -log (P-Val)   Hits   PubMed IDs for Articles with Shared Sentences (# sentences)
    aml adult 85.2 22 12750701 (2), 15054042 (1), 15996732 (1), 10764154 (1) (see all 19)
    leukemogenesis 81.6 32 17485549 (2), 12239147 (2), 14562119 (2), 10505320 (2) (see all 20)
    aml childhood 80.8 29 15166029 (4), 20514303 (3), 15010072 (2), 17763464 (2) (see all 16)
    leukemia 79.8 215 19541823 (6), 17330105 (5), 17332306 (5), 14555522 (4) (see all 99)
    acute leukemia 73.4 56 17584026 (4), 15778081 (3), 17387224 (2), 18925699 (2) (see all 37)
    lymphoblastic leukemia acute 68.2 35 16234090 (2), 18024407 (2), 19968062 (2), 12176867 (1) (see all 28)
    leukemia promyelocytic acute 67.7 26 16105978 (2), 19176014 (2), 17939400 (2), 20096459 (2) (see all 18)
    myelodysplastic syndromes 67.6 27 16902153 (2), 15036894 (2), 16787503 (2), 15257941 (2) (see all 23)
    minimal residual disease 64 12 12239147 (3), 15645287 (2), 19176010 (1), 12854887 (1) (see all 6)
    myeloproliferative disorders 63.8 8 16761019 (2), 16557239 (1), 16938665 (1), 17076649 (1) (see all 7)

    Genetic Association Database (GAD): FLT3
    Human Genome Epidemiology (HuGE) Navigator: FLT3 (128 documents)

    Export disorders for FLT3 gene to outside databases

    (in PubMed. Associations of this gene to articles via 1Entrez Gene, 2UniProtKB/Swiss-Prot, 3HGNC, 4GAD, 5PharmGKB, 6HMDB, 7DrugBank, 8UniProtKB/TrEMBL, 9 Novoseek, and/or 10fRNAdb)
    About This Section

    PubMed articles for FLT3 gene, integrated from 9 sources (see all 1071) (see top 10):
    (articles sorted by number of sources associating them with FLT3)
        Utopia: connect your pdf to the dynamic
    world of online information

    1. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. (PubMed id 8394751)1, 2, 3, 9 Rosnet O.... Birnbaum D. (1993)
    2. [Correlation of FLT3 gene expression level and internal tandem duplication mutation in acute myeloid leukemia and its clinical significance] (PubMed id 19176010)1, 4, 9 Wang Y.G....Jin J. (2008)
    3. [Correlation of Fms-like tyrosine kinase 3 (FLT3) gen e expression to FLT3/internal tandem duplication mutation in peripheral blood o f acute myeloid leukemia.] (PubMed id 19635202)1, 4, 9 Xu B....Zhou S.Y. (2009)
    4. Mutations of the FLT3 gene in adult acute myeloid leukemia: determination of incidence and identification of a novel mutation in a Thai population. (PubMed id 16213360)1, 4, 9 Auewarakul C.U....Yenchitsomanus P.T. (2005)
    5. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. (PubMed id 14654525)1, 7, 9 O'Farrell A.M....Cherrington J.M. (2003)
    6. Structural and functional alterations of FLT3 in acut e myeloid leukemia. (PubMed id 19549778)1, 2, 9 Meshinchi S. and Appelbaum F.R. (2009)
    7. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. (PubMed id 18490735)1, 2, 9 Kikushige Y....Akashi K. (2008)
    8. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. (PubMed id 17910045)1, 4, 9 Paulsson K....Johansson B. (2008)
    9. Detection of FLT3 gene and FLT3/ITD mutation by polymerase chain reaction-single-strand conformation polymorphism in patients with acute lymphoblastic leukemia. (PubMed id 16234090)1, 4, 9 Xu B....Zhou S.Y. (2005)
    10. High transcript level of FLT3 associated with high ri sk of relapse in pediatric acute myeloid leukemia. (PubMed id 20514303)1, 4, 9 Kang H.J....Ahn H.S. (2010)
    11. Association of FLT3 polymorphisms with low BMD and risk of osteoporotic fracture in postmenopausal women. (PubMed id 17620055)1, 4, 9 Koh J.M....Park E.K. (2007)
    12. Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene. (PubMed id 17064989)1, 4, 9 Yoo S.J....Chi H.S. (2006)
    13. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. (PubMed id 15059064)1, 4, 9 Andersson A....Fioretos T. (2004)
    14. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. (PubMed id 8946930)1, 2, 9 Nakao M....Misawa S. (1996)
    15. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. (PubMed id 7507245)1, 2, 9 Small D.... Civin C.I. (1994)
    16. Clinical relevance of FLT3 gene abnormalities in Brazilian patients with infant leukemia. (PubMed id 19052976)1, 4, 9 Emerenciano M....Pombo-de-Oliveira M.S. (2008)
    17. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. (PubMed id 17229632)1, 7, 9 Lierman E....Cools J. (2007)
    18. PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia. (PubMed id 16533526)1, 4, 9 Yamamoto T....Kojma S. (2006)
    19. Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. (PubMed id 16684964)1, 2, 9 Heiss E....Ronnstrand L. (2006)
    20. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. (PubMed id 15973451)1, 4, 9 Noguera N.I....Lo-Coco F. (2005)
    21. Prognostic significance of FLT3 internal tandem dupli cation and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. (PubMed id 20096459)1, 4, 9 Beitinjaneh A....Majhail N.S. (2010)
    22. Prevalence and prognostic significance of FLT3 gene m utations in patients with acute leukaemia: analysis of patients from the Shangh ai Leukaemia Co-operative Group. (PubMed id 20515557)1, 4, 9 Wang W....Lin G.W. (2010)
    23. Monitoring of minimal residual disease in patients wi th core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, an d JAK2 mutations on clinical outcome. (PubMed id 19603346)1, 4, 9 MarkovA! J....Schwarz J. (2009)
    24. [FLT3 mutation in patients with acute lymphoblastic l eukemia and its clinical significance] (PubMed id 19968062)1, 4, 9 Zhao X....Wang J.X. (2009)
    25. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. (PubMed id 18450602)1, 4, 9 Schlenk R.F....Dohner H. (2008)
    26. [Prevalence and clinical significance of FLT3 mutations in acute promyelocytic leukemia] (PubMed id 19176014)1, 4, 9 Xue M.X....Wu D.P. (2008)
    27. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups. (PubMed id 18977345)1, 4, 9 Sritana N. and Auewarakul C.U. (2008)
    28. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. (PubMed id 18270328)1, 4, 9 Tomasson M.H....Ley T.J. (2008)
    29. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. (PubMed id 18081718)1, 4, 9 Scholl S....Wedding U. (2008)
    30. Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population. (PubMed id 18192111)1, 4, 9 Suzuki R....Ando K. (2007)
    31. Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia. (PubMed id 15863200)1, 4, 9 Kang H.J....Ahn H.S. (2005)
    32. [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia] (PubMed id 16185475)1, 4, 9 Wang L.H....Wang J.X. (2005)
    33. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. (PubMed id 15959528)1, 4, 9 Yanada M....Naoe T. (2005)
    34. The impact on outcome of the addition of all-trans re tinoic acid to intensive chemotherapy in younger patients with nonacute promyel ocytic acute myeloid leukemia: overall results and results in genotypic subgrou ps defined by mutations in NPM1, FLT3, and CEBPA. (PubMed id 19965647)1, 4, 9 Burnett A.K....Gale R.E. (2010)
    35. Phase I/II study of combination therapy with sorafeni b, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. (PubMed id 20212254)1, 4, 9 Ravandi F....Kantarjian H.M. (2010)
    36. Genetic changes including gene copy number alteration s and their relation to prognosis in childhood acute myeloid leukemia. (PubMed id 20001230)1, 4, 9 Armengol G....Knuutila S. (2010)
    37. Detection of KIT and FLT3 mutations in acute myeloid leukemia with different subtypes. (PubMed id 20039765)1, 4, 9 Zaker F....Mohammadi M. (2010)
    38. A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia. (PubMed id 19181784)1, 4, 9 Iwanaga E....Asou N. (2009)
    39. Frequent genomic abnormalities in acute myeloid leuke mia/myelodysplastic syndrome with normal karyotype. (PubMed id 19144660)1, 4, 9 Akagi T....Koeffler H.P. (2009)
    40. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia. (PubMed id 19309322)1, 4, 9 Ishikawa Y....Naoe T. (2009)
    41. Wilms tumor 1 gene mutations are associated with a hi gher risk of recurrence in young adults with acute myeloid leukemia: a study fr om the Acute Leukemia French Association. (PubMed id 19536888)1, 4, 9 Renneville A....Preudhomme C. (2009)
    42. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. (PubMed id 19059939)1, 4, 9 Schlenk R.F....DAPhner H. (2009)
    43. Genome wide molecular analysis of minimally different iated acute myeloid leukemia. (PubMed id 19773259)1, 4, 9 Silva F.P....Giphart-Gassler M. (2009)
    44. Structural and numerical variation of FLT3/ITD in pediatric AML. (PubMed id 18305215)1, 2, 9 Meshinchi S....Radich J.P. (2008)
    45. Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia. (PubMed id 19085113)1, 4, 9 Braoudaki M....Tzortzatou-Stathopoulou F. (2008)
    46. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. (PubMed id 17957027)1, 4, 9 Gale R.E....Linch D.C. (2008)
    47. Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood AML Cooperative Study Group. (PubMed id 17763464)1, 4, 9 Shimada A....Hayashi Y. (2008)
    48. Low frequency and variability of FLT3 mutations in Korean patients with acute myeloid leukemia. (PubMed id 18955790)1, 4, 9 Bang S.M....Ahn H.S. (2008)
    49. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. (PubMed id 17606455)1, 4, 9 Mathews V....Chandy M. (2007)
    50. D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias. (PubMed id 16320249)1, 4, 9 Schnittger S....Spiekermann K. (2006)
    51. Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases. (PubMed id 15831474)1, 2, 9 Schmidt-Arras D.E....Bohmer F.D. (2005)
    52. Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients. (PubMed id 15996732)1, 4, 9 Wang L....Wang J. (2005)
    53. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. (PubMed id 16076867)1, 4, 9 Schnittger S....Falini B. (2005)
    54. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. (PubMed id 14504097)1, 2, 9 Taketani T....Hayashi Y. (2004)
    55. CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication. (PubMed id 12468438)1, 4, 9 Bowen D.T....Morgan G.J. (2003)
    56. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. (PubMed id 11290608)1, 2, 9 Yamamoto Y....Naoe T. (2001)
    57. Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. (PubMed id 2004790)1, 2, 9 Rosnet O.... Birnbaum D. (1991)
    58. Activity of ponatinib against clinically-relevant AC22 0-resistant kinase domain mutants of FLT3-ITD. (PubMed id 23430109)1, 7 Smith C.C....Shah N.P. (2013)
    59. Further activation of FLT3 mutants by FLT3 ligand. (PubMed id 21516120)1, 2 Zheng R....Small D. (2011)
    60. Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex. (PubMed id 21389326)1, 2 Verstraete K.... Savvides S.N. (2011)
    61. Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling. (PubMed id 21262971)1, 2 Arora D....MA1ller J.P. (2011)
    62. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leuk emia. (PubMed id 21173125)1, 4 Bains A....Zuo Z. (2011)
    63. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukem ia and normal karyotype. (PubMed id 20023256)1, 4 Luo J....Chang H. (2010)
    64. The prognostic significance of IDH1 mutations in youn ger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. (PubMed id 20651067)1, 4 Green C.L....Gale R.E. (2010)
    65. Incidence and significance of FLT3-ITD and NPM1 mutat ions in patients with normal karyotype acute myeloid leukaemia. (PubMed id 20803351)1, 4 Haslam K....Langabeer S.E. (2010)
    66. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. (PubMed id 20379614)1, 4 Rose J.E....Uhl G.R. (2010)
    67. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. (PubMed id 20520634)1, 4 Dicker F....Schnittger S. (2010)
    68. Results of FLT3 mutation screening and correlations w ith immunophenotyping in 169 Brazilian patients with acute myeloid leukemia. (PubMed id 19921191)1, 4 Lucena-Araujo A.R....Rego E.M. (2010)
    69. Novel immunophenotypic and morphologic presentation i n acute myeloid leukemia (AML) with JAK2 V617F mutation. (PubMed id 19824900)1, 4 Swaminathan S....Gupta M. (2010)
    70. Favorable outcome in patients with acute myeloid leuk emia with NPM1 mutation autografted after conditioning with high dose continuou s infusion idarubicin and busulphan. (PubMed id 20172040)1, 4 Ferrara F....Palmieri S. (2010)
    71. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, J AK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes a nd acute myeloid leukemias. (PubMed id 20678218)1, 4 Rocquain J....Mozziconacci M.J. (2010)
    72. Analysis of FLT3-ITD and FLT3-Asp835 mutations in de novo acute myeloid leukemia: evaluation of incidence, distribution pattern, cor relation with cytogenetics and characterization of internal tandem duplication from Indian population. (PubMed id 19995225)1, 4 Ahmad F....Das B.R. (2010)
    73. High-frequency type I/II mutational shifts between di agnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. (PubMed id 20592250)1, 4 Bachas C....Cloos J. (2010)
    74. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporat ion into a survival scoring system. (PubMed id 20368469)1, 4 Hou H.A....Tien H.F. (2010)
    75. ETS-related gene ERG expression in AML patients is si gnificantly associated with NPM1 mutation status. (PubMed id 20546020)1, 4 HAomAolAoinen M....Kairisto V. (2010)
    76. Molecular alterations of the IDH1 gene in AML: a Chil dren's Oncology Group and Southwest Oncology Group study. (PubMed id 20376086)1, 4 Ho P.A....Meshinchi S. (2010)
    77. Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations. (PubMed id 20981678)1, 4 Singh H....Attar E. (2010)
    78. Variation at the NFATC2 locus increases the risk of t hiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipr il and rosiglitazone Medication (DREAM) study. (PubMed id 20628086)1, 4 Bailey S.D....Anand S. (2010)
    79. FLT3 internal tandem duplication and FLT3-D835 mutati on in 80 AML patients categorized into cytogenetic risk groups. (PubMed id 20966504)1, 4 MaA8y E....Januszkiewicz D. (2010)
    80. FLT3 internal tandem duplication associates with adve rse outcome and gene- and microRNA-expression signatures in patients 60 years o f age or older with primary cytogenetically normal acute myeloid leukemia: a Ca ncer and Leukemia Group B study. (PubMed id 20656931)1, 4 Whitman S.P....Bloomfield C.D. (2010)
    81. mTOR signaling is activated by FLT3 kinase and promot es survival of FLT3-mutated acute myeloid leukemia cells. (PubMed id 21067588)1, 2 Chen W....Rassidakis G.Z. (2010)
    82. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. (PubMed id 20880116)1, 4 Gelsi-Boyer V....Birnbaum D. (2010)
    83. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cyto metry improves risk stratification in adult acute myeloid leukemia. (PubMed id 20548095)1, 4 Buccisano F....Venditti A. (2010)
    84. Human Variation in Alcohol Response Is Influenced by Variation in Neuronal Signaling Genes. (PubMed id 20201926)1, 4 Joslyn G....White R.L. (2010)
    85. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. (PubMed id 20439648)1, 4 Green C.L....Gale R.E. (2010)
    86. C/EBPA gene mutation and C/EBPA promoter hypermethyla tion in acute myeloid leukemia with normal cytogenetics. (PubMed id 20513120)1, 4 Lu Y....Huang Q. (2010)
    87. DNMT3A mutations in acute myeloid leukemia. (PubMed id 21067377)1, 4 Ley T.J....Wilson R.K. (2010)
    88. Ubiquitin conjugase UBCH8 targets active FMS-like tyr osine kinase 3 for proteasomal degradation. (PubMed id 20508617)1, 2 Buchwald M....KrAomer O.H. (2010)
    89. The IFNG (IFN-gamma) genotype predicts cytogenetic an d molecular response to imatinib therapy in chronic myeloid leukemia. (PubMed id 20959405)1, 4 Kim D.H....Lipton J.H. (2010)
    90. Impact of IDH1 R132 mutations and an IDH1 single nucl eotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs115 54137 is an adverse prognostic factor. (PubMed id 20368538)1, 4 Wagner K....Krauter J. (2010)
    91. Investigation of genetic susceptibility factors for h uman longevity - A targeted nonsynonymous SNP study. (PubMed id 20800603)1, 4 Flachsbart F....Nebel A. (2010)
    92. Mutual exclusion of ASXL1 and NPM1 mutations in a ser ies of acute myeloid leukemias. (PubMed id 19865112)1, 4 Carbuccia N....Mozziconacci M.J. (2009)
    93. Cytoplasmic localization of nucleophosmin in bone mar row blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. (PubMed id 19637342)1, 4 Konoplev S....Bueso-Ramos C.E. (2009)
    94. Incidence of FLT3 and nucleophosmin gene mutations in childhood acute myeloid leukemia: Serbian experience and the review of the lit erature. (PubMed id 19557552)1, 4 Krstovski N....Pavlovic S. (2009)
    95. [FMS-like tyrosine kinase 3 gene mutations in acute m yeloid leukemia] (PubMed id 19840437)1, 4 Han Y.L....Li J.Y. (2009)
    96. Genetic mutations associated with cigarette smoking in pancreatic cancer. (PubMed id 19351817)1, 4 Blackford A....Hruban R.H. (2009)
    97. Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. (PubMed id 19141860)1, 4 Kim D.H....Lipton J.H. (2009)
    98. A high-throughput candidate gene mutation screen in l ymphoproliferative and myeloproliferative neoplasias. (PubMed id 19464057)1, 4 Kreil S....Chase A. (2009)
    99. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. (PubMed id 19221039)1, 4 Gaidzik V.I....DAPhner K. (2009)
    100. The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. (PubMed id 19151774)1, 4 Seifert H....Schaich M. (2009)
    101. FLT3 mutations have no prognostic impact in elderly p atients with acute myeloid leukemia and normal karyotype. (PubMed id 19562748)1, 4 Ferrara F....Pane F. (2009)
    102. Fulfilling the promise of personalized medicine? Syst ematic review and field synopsis of pharmacogenetic studies. (PubMed id 19956635)1, 4 Holmes M.V....Casas J.P. (2009)
    103. Cuplike nuclei (prominent nuclear invaginations) in a cute myeloid leukemia are highly associated with FLT3 internal tandem duplicati on and NPM1 mutation. (PubMed id 19672946)1, 4 Chen W....Bueso-Ramos C.E. (2009)
    104. Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene muta tions in chronic myelomonocytic leukemia. (PubMed id 19540590)1, 4 Chen W. and Huang Q. (2009)
    105. Wilms Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. (PubMed id 18559874)1, 4 Paschka P....Bloomfield C.D. (2008)
    106. Detection of FLT3 Oncogene Mutations in Acute Myeloid Leukemia Using Conformation Sensitive Gel Electrophoresis. (PubMed id 19330068)1, 4 Gari M....Damanhouri G. (2008)
    107. Prognostic significance of foetal-like tyrosine kinase 3 mutation in Egyptian children with acute leukaemia. (PubMed id 18336585)1, 4 Al-Tonbary Y....Abd-Elghaffar H.A. (2008)
    108. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. (PubMed id 17550846)1, 4 Bacher U....Schnittger S. (2007)
    109. [A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia] (PubMed id 18261272)1, 4 Wu D.P....Liang J.Y. (2007)
    110. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. (PubMed id 16046528)1, 4 Boissel N....Preudhomme C. (2005)
    111. Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia. (PubMed id 16029447)1, 4 Kuchenbauer F....Schnittger S. (2005)
    112. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. (PubMed id 16015387)1, 4 Goemans B.F....Heinrich M.C. (2005)
    113. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). (PubMed id 15902284)1, 4 Nanri T....Asou N. (2005)
    114. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. (PubMed id 14759363)1, 2 Griffith J....Saxena K. (2004)
    115. The role of FLT3 in haematopoietic malignancies. (PubMed id 12951584)1, 2 Stirewalt D.L. and Radich J.P. (2003)
    116. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. (PubMed id 11442493)1, 2 Abu-Duhier F.M....Reilly J.T. (2001)
    117. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. (PubMed id 10080542)1, 2 Zhang S....Broxmeyer H.E. (1999)
    118. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations. (PubMed id 15781338)1, 9 Robinson L.J....Corey S.J. (2005)
    119. [Dynamic detection of FLT3 gene in patients with AML and its significance] (PubMed id 17708787)1, 9 Li S....Zhang L. (2007)
    120. Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells. (PubMed id 18797870)1, 9 Weisel K.C....MAPhle R. (2009)
    121. Fms-like tyrosine kinase (FLT) 3 and FLT3 internal tandem duplication in different types of adult leukemia: analysis of 147 patients. (PubMed id 18925699)1, 9 Peng H.L....Yang J.J. (2008)
    122. FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells. (PubMed id 17851558)1, 9 Kajiguchi T....Trepel J.B. (2007)
    123. Oncogenic Flt3 receptors display different specificit y and kinetics of autophosphorylation. (PubMed id 19477218)2, 9 Razumovskaya E....RAPnnstrand L. (2009)
    124. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation. (PubMed id 16982329)1, 9 Hartman A.D....Boswell H.S. (2006)
    125. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. (PubMed id 12681969)1, 9 Bruserud O....Gjertsen B.T. (2003)
    126. Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner. (PubMed id 17668209)1, 9 Mitina O....Obermeier A. (2007)
    127. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges. (PubMed id 15604885)1, 9 Sternberg D.W. and Licht J.D. (2005)
    128. Flt3 receptor tyrosine kinase as a drug target in leukemia. (PubMed id 15180525)7, 9 Schmidt-Arras D....Serve H. (2004)
    129. Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. (PubMed id 12676789)1, 9 Sitnicka E....Jacobsen S.E. (2003)
    130. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. (PubMed id 12239147)1, 9 Kottaridis P.D....Linch D.C. (2002)
    131. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. (PubMed id 9737679)2, 9 Kiyoi H....Naoe T. (1998)
    132. The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations. (PubMed id 18071308)1, 9 Odgerel T....Furukawa Y. (2008)
    133. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. (PubMed id 17498302)1, 9 Wergeland L....Gjertsen B.T. (2007)
    134. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). (PubMed id 15345593)1, 9 Kindler T....Fischer T. (2005)
    135. Normal and oncogenic FLT3. (PubMed id 15583855)1, 9 Naoe T. and Kiyoi H. (2004)
    136. RNA interference screen in primary human T cells reve als FLT3 as a modulator of IL-10 levels. (PubMed id 20018615)1, 9 Astier A.L....Hacohen N. (2010)
    137. Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. (PubMed id 18670883)1, 9 Grosjean-Raillard J....Kroemer G. (2008)
    138. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. (PubMed id 17485549)1, 9 Dicker F....Schnittger S. (2007)
    139. Effect of FLT3 inhibition on normal hematopoietic progenitor cells. (PubMed id 17442779)1, 9 Weisel K.C....Mohle R. (2007)
    140. Implications of FLT3 mutations in the therapy of acute myeloid leukemia. (PubMed id 18473998)1, 9 Mattison R.J....Godley L.A. (2007)
    141. FLT3 as a therapeutic target in childhood acute leukemia. (PubMed id 17584026)1, 9 Stubbs M.C. and Armstrong S.A. (2007)
    142. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. (PubMed id 16410449)1, 9 Reindl C....Spiekermann K. (2006)
    143. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. (PubMed id 15150124)1, 9 George P....Bhalla K. (2004)
    144. p85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells. (PubMed id 9918857)1, 9 Zhang S. and Broxmeyer H.E. (1999)
    145. Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13q12-->q13. (PubMed id 7789184)1, 9 Carow C.E....Small D. (1995)
    146. Oncogenic signaling from the hematopoietic growth fac tor receptors c-Kit and Flt3. (PubMed id 19540337)1, 9 Masson K. and RAPnnstrand L. (2009)
    147. [FLT3 Gene Mutations as a Prognostic Factor for Acute Myeloid Leukemia.] (PubMed id 18156731)1, 9 Chang S.H....Suh J.S. (2006)
    148. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. (PubMed id 15166029)1, 9 Brown P....Small D. (2004)
    149. Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype. (PubMed id 14562119)1, 9 Matsuno N....Asou N. (2003)
    150. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. (PubMed id 10698507)1, 9 Hayakawa F....Naoe T. (2000)
    151. [Tyrosine kinase mutation and acute myeloid leukemia with T (8; 21)] (PubMed id 19698218)1, 9 Han Y.L....Li J.Y. (2009)
    152. [Clinical significance of FLT3 internal tandem duplication in acute myeloid leukemia with chromosome abnormality] (PubMed id 17708786)1, 9 Wang J....Wang T. (2007)
    153. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. (PubMed id 18024407)1, 9 Stam R.W....Pieters R. (2007)
    154. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation. (PubMed id 17598835)1, 9 Mori Y....Harada M. (2007)
    155. Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients. (PubMed id 17650443)1, 9 Silva F.P....Giphart-Gassler M. (2007)
    156. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). (PubMed id 16598313)1, 9 Boissel N.... . (2006)
    157. Trisomy 11 in myeloid malignancies is associated with internal tandem duplication of both MLL and FLT3 genes. (PubMed id 15710585)1, 9 Rege-Cambrin G....Hagemeijer A. (2005)
    158. Mutant FLT3 signaling contributes to a block in myeloid differentiation. (PubMed id 16263569)1, 9 Zheng R. and Small D. (2005)
    159. [FLT3 gene mutation and its prognostic implication in patients with acute leukemia.] (PubMed id 20302766)1, 9 (2010)
    160. Long FLT3 internal tandem duplications and reduced PM L-RARalpha expression at diagnosis characterize a high-risk subgroup of acute p romyelocytic leukemia patients. (PubMed id 20133893)1, 9 ChillA^n M.C....GonzA!lez M. (2010)
    161. Synergistic protecting effect of cord blood CD34+ cel ls over-expressing both interleukin-3 and Flt3 ligand on lethally irradiated mi ce. (PubMed id 19529981)1, 9 Zhang Y....Dong S. (2009)
    162. FLT3 inhibition as a targeted therapy for acute myelo id leukemia. (PubMed id 19684517)1, 9 Sanz M....LAPwenberg B. (2009)
    163. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia. (PubMed id 18503825)1, 9 Pinheiro R.F....Chauffaille M.d.e. .L. (2008)
    164. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. (PubMed id 18394702)1, 9 Nishioka C....Yokoyama A. (2008)
    165. [FLT3 internal tandem duplication in patients with acute promyelocytic leukemia] (PubMed id 17939400)1, 9 Zhu Y.M....Hu J. (2007)
    166. Antitumor activity of sorafenib in FLT3-driven leukemic cells. (PubMed id 17205056)7, 9 Auclair D....Wilhelm S.M. (2007)
    167. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. (PubMed id 17456725)1, 9 Mead A.J....Gale R.E. (2007)
    168. Arginine 595 is duplicated in patients with acute leu kemias carrying internal tandem duplications of FLT3 and modulates its transfor ming potential. (PubMed id 17387224)1, 9 Vempati S....Spiekermann K. (2007)
    169. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. (PubMed id 16116483)1, 9 Lee B.H....Gilliland D.G. (2005)
    170. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. (PubMed id 16266983)2, 9 Brandts C.H....Serve H. (2005)
    171. Analyses of minimal residual disease based on Flt3 mutations in allogeneic peripheral blood stem cell transplantation. (PubMed id 15645287)1, 9 Scholl S....Sayer H.G. (2005)
    172. Low frequency of FLT3 gene internal tandem duplication and activating loop mutation in therapy-related acute myelocyticleukemia and myelodysplastic syndrome. (PubMed id 15036894)4, 9 Au W.Y....Kwong Y.L. (2004)
    173. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. (PubMed id 14604974)1, 9 Bagrintseva K....Spiekermann K. (2004)
    174. Analysis of the activating mutations within the activation loop of leukemia targets Flt-3 and c-Kit based on protein homology modeling. (PubMed id 15363457)1, 9 Torrent M....Sepp-Lorenzino L. (2004)
    175. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. (PubMed id 12468433)1, 9 Mizuki M....Serve H. (2003)
    176. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. (PubMed id 12973844)4, 9 Shih L.Y....Lai C.L. (2003)
    177. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. (PubMed id 11971190)1, 9 Kiyoi H....Naoe T. (2002)
    178. Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase. (PubMed id 11027663)1, 9 Zhang S. and Broxmeyer H.E. (2000)
    179. The FLT3 internal tandem duplication mutation is a se condary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogeno us leukemia cells. (PubMed id 20159992)1, 9 Grundy M....Pallis M. (2010)
    180. Relapsed childhood high hyperdiploid acute lymphoblas tic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations. (PubMed id 20237506)1, 9 Davidsson J....Johansson B. (2010)
    181. [Correlation of adult AML Npm1 mutations with prognos is and its relationship with gene mutation of FLT3 and CEBPA] (PubMed id 20137111)1, 9 Bao L.Y. and Wang J.S. (2010)
    182. FLT3-ITD up-regulates MCL-1 to promote survival of st em cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. (PubMed id 19808698)1, 9 Yoshimoto G....Akashi K. (2009)
    183. FLT3-ITD expression levels and their effect on STAT5 in AML with and without NPM mutations. (PubMed id 19775300)1, 9 Seedhouse C.H....Russell N.H. (2009)
    184. The juxtamembrane domain in ETV6/FLT3 is critical for PIM-1 up-regulation and cell proliferation. (PubMed id 19345670)1, 9 Vu H.A....Sato Y. (2009)
    185. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. (PubMed id 19853583)1, 9 Jin G....Miyachi H. (2009)
    186. Absence of FLT3 and JAK2 (V617F) mutations in Langerh ans cell histiocytosis. (PubMed id 19395028)1, 9 Abedalthagafi M....Ozdemirli M. (2009)
    187. FLT3 mutations in a 10 year consecutive series of 177 childhood acute leukemias and their impact on global gene expression patterns. (PubMed id 17943971)1, 9 Andersson A....Fioretos T. (2008)
    188. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. (PubMed id 17940205)1, 9 Whitman S.P....Bloomfield C.D. (2008)
    189. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. (PubMed id 17851551)1, 9 Stubbs M.C....Armstrong S.A. (2008)
    190. Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene. (PubMed id 17983653)1, 9 Nishioka C....Yokoyama A. (2008)
    191. Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations. (PubMed id 18641025)1, 9 Boonthimat C....Auewarakul C.U. (2008)
    192. Acute promyelocytic leukemia with t(15;17): frequency of additional clonal chromosome abnormalities and FLT3 mutations. (PubMed id 19052993)1, 9 De Lourdes Chauffaille M....Alberto F.L. (2008)
    193. Activating mutations in human acute megakaryoblastic leukemia. (PubMed id 18755984)1, 9 Malinge S....Bernard O.A. (2008)
    194. [Detection of FLT3 gene mutation in hematologic malignancies and its clinical significance] (PubMed id 17708788)1, 9 Liu H....Guo C.J. (2007)
    195. Identification of TSC-22 as a potential tumor suppressor that is upregulated by Flt3-D835V but not Flt3-ITD. (PubMed id 17690703)1, 9 Lu Y....Kitamura T. (2007)
    196. Specific pattern of protein expression in acute myeloid leukemia harboring FLT3-ITD mutations. (PubMed id 18067018)1, 9 Scholl S....von Eggeling F. (2007)
    197. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia. (PubMed id 17881645)1, 9 Stam R.W....Pieters R. (2007)
    198. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. (PubMed id 17230226)1, 9 Okamoto M....Naoe T. (2007)
    199. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. (PubMed id 18068628)1, 9 Frohling S....Gilliland D.G. (2007)
    200. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. (PubMed id 17936561)1, 9 Lee B.H....Gilliland D.G. (2007)
    201. Analysis of FLT3 gene mutations in de novo myelodysplastic syndromes. FLT3 internal tandem duplication detected in a case of refractory anemia. (PubMed id 18067020)1, 9 Pappa V....Economopoulos T. (2007)
    202. Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia. (PubMed id 18024405)1, 9 de Vries A.C....van den Heuvel-Eibrink M.M. (2007)
    203. Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype. (PubMed id 17036374)1, 9 Palmieri S....Pane F. (2007)
    204. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. (PubMed id 16642044)1, 9 Cloos J....Kaspers G.J. (2006)
    205. The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia. (PubMed id 16861351)1, 9 Palmqvist L....Humphries R.K. (2006)
    206. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). (PubMed id 16990784)1, 9 Schittenhelm M.M....Heinrich M.C. (2006)
    207. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. (PubMed id 16410383)1, 9 Parcells B.W....Sakamoto K.M. (2006)
    208. FLT-3: a new focus in the understanding of acute leukemia. (PubMed id 15778081)1, 9 Markovic A....Lock R.B. (2005)
    209. Activating FLT3 mutations in CD4+/CD8- pediatric T-cell acute lymphoblastic leukemias. (PubMed id 16326981)1, 9 Van Vlierberghe P....Pieters R. (2005)
    210. FLT3/ITD mutation signaling includes suppression of SHP-1. (PubMed id 15574429)1, 9 Chen P....Small D. (2005)
    211. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. (PubMed id 15604894)1, 9 Marcucci G....Bloomfield C.D. (2005)
    212. The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. (PubMed id 14982881)1, 9 Takahashi S....Licht J.D. (2004)
    213. FLT3 mutations in childhood acute lymphoblastic leukemia. (PubMed id 14670924)1, 9 Armstrong S.A....Korsmeyer S.J. (2004)
    214. FLT3 mutations are associated with other molecular lesions in AML. (PubMed id 14630076)1, 9 Carnicer M.J....Sierra J. (2004)
    215. FLT3 mutations in myeloid sarcoma. (PubMed id 15352981)1, 9 Ansari-Lari M.A....Murphy K.M. (2004)
    216. FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. (PubMed id 15167911)1, 9 Chillon M.C....Miguel J.F. (2004)
    217. Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. (PubMed id 14753710)7, 9 BarattA" S....Zhang Q. (2004)
    218. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. (PubMed id 14737077)1, 9 Shih L.Y....Kuo M.C. (2004)
    219. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. (PubMed id 15044257)1, 9 Paietta E....Look A.T. (2004)
    220. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. (PubMed id 15054042)1, 9 Rombouts E.J....Ploemacher R.E. (2004)
    221. FLT3: receptor and ligand. (PubMed id 15253381)1, 9 Drexler H.G. and Quentmeier H. (2004)
    222. Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia. (PubMed id 15061200)1, 9 Ciolli S....Bosi A. (2004)
    223. Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia. (PubMed id 12854887)1, 9 Kottaridis P.D....Linch D.C. (2003)
    224. FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors. (PubMed id 12935959)1, 9 Gilliland D.G. (2003)
    225. Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. (PubMed id 12842996)1, 9 Minami Y....Naoe T. (2003)
    226. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. (PubMed id 12399960)4, 9 Noguera N.I....Lo Coco F. (2002)
    227. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. (PubMed id 11133746)1, 9 Meshinchi S....Radich J.P. (2001)
    228. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. (PubMed id 11090077)2, 9 Mizuki M....Serve H. (2000)
    229. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. (PubMed id 8637232)2, 9 Rosnet O....Birnbaum D. (1996)
    230. Receptor kinase profiles identify a rationale for mult itarget kinase inhibition in immature T-ALL. (PubMed id 22751451)1 Lhermitte L....Asnafi V. (2013)
    231. Favorable outcome of patients with acute myeloid leuke mia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutati on: relevance to post-remission therapy. (PubMed id 23377436)1 Pratcorona M....Esteve J. (2013)
    232. FLT3 mutations in patients with childhood acute lympho blastic leukemia (ALL). (PubMed id 23335073)1 Kabir N.N....Kazi J.U. (2013)
    233. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leuke mia: implications for Axl as a potential therapeutic target. (PubMed id 23321254)1 Park I.K....Caligiuri M.A. (2013)
    234. Prognostic impact of allogeneic hematopoietic stem cel l transplantation for acute myeloid leukemia patients with internal tandem dupli cation of FLT3. (PubMed id 23276395)1 Lin P.H....Yeh S.P. (2013)
    235. NPM1, FLT3, and c-KIT mutations in pediatric acute mye loid leukemia in Russian population. (PubMed id 23511494)1 Yatsenko Y....Nasedkina T. (2013)
    236. FLT3 mutations in early T-cell precursor ALL character ize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhi bitors. (PubMed id 23359050)1 Neumann M....Baldus C.D. (2013)
    237. Molecular analysis of different FLT3-ITD mutations in acute myeloid leukemia. (PubMed id 22721497)1 Blau O....Blau I.W. (2013)
    238. Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia. (PubMed id 23238897)1 Park B.G....Lee K.H. (2013)
    239. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. (PubMed id 23115106)1 Daver N....Garcia-Manero G. (2013)
    240. High FLT3 expression and IL10 (G1082A) polymorphism in poor overall survival in calla acute lymphoblastic leukemia. (PubMed id 23086275)1 de Deus D.M....Muniz M.T. (2013)
    241. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations. (PubMed id 22914610)1 Rollins-Raval M....Roth C.G. (2013)
    242. Mutations of FLT3/ITD confer resistance to multiple ty rosine kinase inhibitors. (PubMed id 22858906)1 Williams A.B....Small D. (2013)
    243. Autotaxin is expressed in FLT3-ITD positive acute myel oid leukemia and hematopoietic stem cells and promotes cell migration and prolif eration. (PubMed id 23377000)1 Ortlepp C....Thiede C. (2013)
    244. Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects. (PubMed id 23124877)1 Klein O....Cebon J. (2013)
    245. Identification of emerging FLT3 ITD-positive clones du ring clinical remission and kinetics of disease relapse in acute myeloid leukaem ia with mutated nucleophosmin. (PubMed id 23480665)1 Ottone T....Lo-Coco F. (2013)
    246. The preferential occurrence of FLT3-TKD mutations in i nv(16) AML and impact on survival outcome: a combined analysis of 1053 core-bind ing factor AML patients. (PubMed id 23190472)1 Kok C.H....D'Andrea R.J. (2013)
    247. Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling. (PubMed id 23548639)1 Kazi J.U. and Ronnstrand L. (2013)
    248. Mutations of the epigenetics-modifying gene (DNMT3a, T ET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloi d leukemia. (PubMed id 23135354)1 Wakita S....Inokuchi K. (2013)
    249. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. (PubMed id 23603912)1 Neumann M....Baldus C.D. (2013)
    250. BCL11B, FLT3, NOTCH1 and FBXW7 mutation status in T-ce ll acute lymphoblastic leukemia patients. (PubMed id 23040356)1 Kraszewska M.D....Witt M. (2013)
    251. Phase 2 study of azacytidine plus sorafenib in patient s with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. (PubMed id 23613521)1 Ravandi F....Levis M. (2013)
    252. Refining the diagnosis and prognostic categorization o f acute myeloid leukemia patients with an integrated use of cytogenetic and mole cular studies. (PubMed id 23154527)1 Costa D....Campo E. (2013)
    253. C/EBPa and MYB regulate FLT3 expression in AML. (PubMed id 23340802)1 Volpe G....Dumon S. (2013)
    254. FLT3 activation cooperates with MLL-AF4 fusion protein to abrogate the hematopoietic specification of human ESCs. (PubMed id 23479570)1 Bueno C....Menendez P. (2013)
    255. FLT3-driven redox-modulation of Ezrin regulates leukae mic cell migration. (PubMed id 23009217)1 Corcoran A. and Cotter T.G. (2013)
    256. Whole-genome-amplified DNA as a source for mutational analysis underestimates the frequency of mutations in pediatric acute myeloid le ukemia. (PubMed id 22996295)1 Rosenquist R....Kanduri M. (2013)
    257. Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype. (PubMed id 22858909)1 Bacher U....Haferlach C. (2013)
    258. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progeni tor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors. (PubMed id 23017497)1 Habif G....Gobert-Gosse S. (2013)
    259. Casitas B-lineage lymphoma mutants activate AKT to ind uce transformation in cooperation with class III receptor tyrosine kinases. (PubMed id 23127761)1 Polzer H....Spiekermann K. (2013)
    260. Functional pathway analysis using SCNP of FLT3 recepto r pathway deregulation in AML provides prognostic information independent from m utational status. (PubMed id 23431389)1 Cesano A....Paietta E. (2013)
    261. Clinical implications of non-A-type NPM1 and FLT3 muta tions in patients with normal karyotype acute myeloid leukemia. (PubMed id 22104247)1 Park B.G....Lee K.H. (2012)
    262. H2O2 production downstream of FLT3 is mediated by p22p hox in the endoplasmic reticulum and is required for STAT5 signalling. (PubMed id 22807997)1 Woolley J.F....Cotter T.G. (2012)
    263. Impact of FLT3 internal tandem duplication on the outc ome of related and unrelated hematopoietic transplantation for adult acute myelo id leukemia in first remission: a retrospective analysis. (PubMed id 22291086)1 Brunet S....Rocha V. (2012)
    264. The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype. (PubMed id 22374696)1 Schneider F....Spiekermann K. (2012)
    265. Correlation analysis of p53 protein isoforms with NPM1 /FLT3 mutations and therapy response in acute myeloid leukemia. (PubMed id 21860418)1 Anensen N....Gjertsen B.T. (2012)
    266. Role of misfolded N-CoR mediated transcriptional dereg ulation of Flt3 in acute monocytic leukemia (AML)-M5 subtype. (PubMed id 22514634)1 Nin D.S....Khan M. (2012)
    267. Minimal residual disease monitoring based on FLT3 inte rnal tandem duplication in adult acute myeloid leukemia. (PubMed id 22129478)1 Abdelhamid E....Renneville A. (2012)
    268. Age-dependent frequencies of NPM1 mutations and FLT3-I TD in patients with normal karyotype AML (NK-AML). (PubMed id 21744003)1 Schneider F....Spiekermann K. (2012)
    269. Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia. (PubMed id 22050655)1 Mohan B.P....Linn Y.C. (2012)
    270. Functional dissection of lysine deacetylases reveals t hat HDAC1 and p300 regulate AMPK. (PubMed id 22318606)1 Lin Y.Y....Boeke J.D. (2012)
    271. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by fl ow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia. (PubMed id 22481022)1 Dalal B.I....Hogge D.E. (2012)
    272. CD117 expression is a sensitive but nonspecific predic tor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leuke mia. (PubMed id 22261446)1 Hoehn D....Lin P. (2012)
    273. A noncanonical Flt3ITD/NF-kB signaling pathway repress es DAPK1 in acute myeloid leukemia. (PubMed id 22096027)1 Shanmugam R....Boswell H.S. (2012)
    274. Amount of bone marrow blasts is strongly correlated t o NPM1 and FLT3-ITD mutation rate in AML with normal karyotype. (PubMed id 21621842)1 Haferlach T....Schnittger S. (2012)
    275. Rapid detection of FLT3 exon 20 tyrosine kinase domain mutations in patients with acute myeloid leukemia by high-resolution melting an alysis. (PubMed id 22132874)1 Tan A.Y....Dobrovic A. (2012)
    276. IDH2 mutations are frequent in Chinese patients with a cute myeloid leukemia and associated with NPM1 mutations and FAB-M2 subtype. (PubMed id 22494415)1 Chao H.Y....Zhang R. (2012)
    277. Delayed processing of bone marrow samples reveals a pr ognostic pattern of NME mRNA expression in cytogenetically normal acute myeloid leukemia. (PubMed id 22421058)1 Bach E....Cross M. (2012)
    278. Negative impact of FLT3-ITD mutation on expression of MDR-1 mRNA in adult acute myeloid leukemia. (PubMed id 22591177)1 Nasil/owska-Adamska B. and Solarska I. (2012)
    279. Activating internal tandem duplication mutations of th e fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in pati ents with acute myeloid leukemia. (PubMed id 22532519)1 Nazha A....Ravandi F. (2012)
    280. FMS-like tyrosine kinase 3 internal tandem duplication and the patterns of its gene sequence in 207 Chinese patients with de novo acut e myeloid leukemia. (PubMed id 22208491)1 Zhong L....Ni X. (2012)
    281. Meta-analysis for the potential application of FLT3-T KD mutations as prognostic indicator in non-promyelocytic AML. (PubMed id 21907407)1 Li W....Wang J. (2012)
    282. Cytogenetic and FMS-like tyrosine kinase 3 mutation an alyses in acute promyelocytic leukemia patients. (PubMed id 22562027)1 Yaghmaie M....Ghaffari S.H. (2012)
    283. Cell transformation by FLT3 ITD in acute myeloid leuke mia involves oxidative inactivation of the tumor suppressor protein-tyrosine pho sphatase DEP-1/ PTPRJ. (PubMed id 22438257)1 Godfrey R....Bohmer F.D. (2012)
    284. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid l eukaemia resulting in secondary D835Y mutation: a model for emerging clinical re sistance patterns. (PubMed id 22354205)1 Moore A.S....Linardopoulos S. (2012)
    285. Inhibitors of DNA binding proteins restrict T cell pot ential by repressing Notch1 expression in Flt3-negative common lymphoid progenit ors. (PubMed id 22972921)1 Pereira de Sousa A....Vieira P. (2012)
    286. Suppressor of cytokine signaling 6 (SOCS6) negatively regulates Flt3 signal transduction through direct binding to phosphorylated tyro sines 591 and 919 of Flt3. (PubMed id 22952242)1 Kazi J.U....Ronnstrand L. (2012)
    287. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. (PubMed id 22454318)1 Thol F....Heuser M. (2012)
    288. Molecular involvement and prognostic importance of fms -like tyrosine kinase 3 in acute myeloid leukemia. (PubMed id 23167317)1 Shahab S....Ahmed N. (2012)
    289. Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia. (PubMed id 22705992)1 Chillon M.C....Menendez P. (2012)
    290. Clinical impact of change of FLT3 mutation status in a cute myeloid leukemia patients. (PubMed id 22684224)1 Warren M....Zuo Z. (2012)
    291. The FLT3 and Pim kinases inhibitor SGI-1776 preferenti ally target FLT3-ITD AML cells. (PubMed id 22343664)1 Hospital M.A....Tamburini J. (2012)
    292. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Gr oup. (PubMed id 22378655)1 Kutny M.A....Meshinchi S. (2012)
    293. Diversity of the juxtamembrane and TKD1 mutations (exo ns 13-15) in the FLT3 gene with regards to mutant load, sequence, length, locali zation, and correlation with biological data. (PubMed id 22674490)1 Schnittger S....Haferlach T. (2012)
    294. Impact of numerical variation in FMS-like tyrosine kin ase receptor 3 internal tandem duplications on clinical outcome in normal karyot ype acute myelogenous leukemia. (PubMed id 22605576)1 Borthakur G....Cortes J.E. (2012)
    295. Influence of FLT3-internal tandem duplication allele b urden and white blood cell count on the outcome in patients with intermediate-ri sk karyotype acute myeloid leukemia. (PubMed id 22736495)1 How J....Brandwein J.M. (2012)
    296. Sorafenib treatment of FLT3-ITD(+) acute myeloid leuke mia: favorable initial outcome and mechanisms of subsequent nonresponsiveness as sociated with the emergence of a D835 mutation. (PubMed id 22368270)1 Man C.H....Leung A.Y. (2012)
    297. Patient-specific analysis of FLT3 internal tandem dupl ications for the prognostication and monitoring of acute myeloid leukemia. (PubMed id 22458420)1 Schiller J....Kreuzer K.A. (2012)
    298. [Establishment of a rapid and easy method for simultan eous detection of FLT3-ITD and NPM1 gene mutations in acute myeloid leukemia]. (PubMed id 22487825)1 Lu Y....Jin J. (2012)
    299. Src-Like adaptor protein (SLAP) binds to the receptor tyrosine kinase Flt3 and modulates receptor stability and downstream signaling. (PubMed id 23300935)1 Kazi J.U. and Ronnstrand L. (2012)
    300. Ectopic expression of Flt3 kinase inhibits proliferati on and promotes cell death in different human cancer cell lines. (PubMed id 22422053)1 Oveland E....Fladmark K.E. (2012)
    301. Role of autologous hematopoietic stem cell transplanta tion according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study. (PubMed id 22911473)1 Guieze R....Chevallier P. (2012)
    302. Synthesis of Cis-fused pyran indolocarbazole derivativ es that inhibit FLT3 kinase and the DNA damage kinase, checkpoint kinase 1. (PubMed id 22044003)1 Perron-Sierra F.M....Golsteyn R.M. (2012)
    303. Induction of vascular endothelial growth factor secret ion by childhood acute lymphoblastic leukemia cells via the FLT-3 signaling path way. (PubMed id 22084166)1 Markovic A....Lock R.B. (2012)
    304. Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. (PubMed id 22210879)1 Kang H....Willman C.L. (2012)
    305. FLT3 and NPM1 mutations in a cohort of AML patients an d detection of a novel mutation in tyrosine kinase domain of FLT3 gene from West ern India. (PubMed id 22733614)1 Ghosh K....Vundinti B. (2012)
    306. Y654 of b-catenin is essential for FLT3/ITD-related ty rosine phosphorylation and nuclear localization of b-catenin. (PubMed id 22126602)1 Kajiguchi T....Naoe T. (2012)
    307. Molecular characterization of FLT3 mutations in acute leukemia patients in Pakistan. (PubMed id 23167384)1 Ishfaq M....Rasool M. (2012)
    308. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. (PubMed id 21767516)1 Sharma Lima M. (2011)
    309. Screening for hotspot mutations in PI3K, JAK2, FLT3 an d NPM1 in patients with myelodysplastic syndromes. (PubMed id 21789382)1 Machado-Neto J.A....Saad S.T. (2011)
    310. Downstream molecular pathways of FLT3 in the pathogen esis of acute myeloid leukemia: biology and therapeutic implications. (PubMed id 21453545)1 Takahashi S. (2011)
    311. FLT3 internal tandem duplication is associated with a high relapse rate and central nervous system involvement in acute promyelocyti c leukemia cases: single institutional analysis. (PubMed id 21129033)1 Tashiro H....Shirafuji N. (2011)
    312. An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling. (PubMed id 21233836)1 Flach J....Haferlach C. (2011)
    313. Survey of activated FLT3 signaling in leukemia. (PubMed id 21552520)1 Gu T.L....Polakiewicz R.D. (2011)
    314. FLT3 mutation and expression did not adversely affect clinical outcome of childhood acute leukaemia: a study of 531 Southeast Asian children by the Ma-Spore study group. (PubMed id 21387358)1 Leow S....Yeoh A.E. (2011)
    315. A proteome-wide, quantitative survey of in vivo ubiqui tylation sites reveals widespread regulatory roles. (PubMed id 21890473)1 Wagner S.A....Choudhary C. (2011)
    316. Frequency and prognostic impact of FLT3/ITD mutation in patients with acute myeloid leukaemia. (PubMed id 21674859)1 Govedarovic N. and Marjanovic G. (2011)
    317. [FLT3 mutations in children with acute myeloid leukem ia: a single center study]. (PubMed id 22099191)1 Ruan M....Zhu X.F. (2011)
    318. Prognostic impact of white blood cell count in interm ediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD. (PubMed id 21606167)1 de Jonge H.J....Huls G. (2011)
    319. Acute myeloid leukemia with IDH1 or IDH2 mutation: fr equency and clinicopathologic features. (PubMed id 21173122)4 Patel K.P....Luthra R. (2011)
    320. Concomitant ABCG2 overexpression and FLT3-ITD mutatio n identify a subset of acute myeloid leukemia patients at high risk of relapse. (PubMed id 21523728)1 Tiribelli M....Damiani D. (2011)
    321. FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis. (PubMed id 21487043)1 Desterke C.... . (2011)
    322. Elevated frequencies of leukemic myeloid and plasmacy toid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem du plication. (PubMed id 21520003)1 Rickmann M....Stripecke R. (2011)
    323. Inhibition of MEK5 by BIX02188 induces apoptosis in c ells expressing the oncogenic mutant FLT3-ITD. (PubMed id 21820407)1 Razumovskaya E....RAPnnstrand L. (2011)
    324. Outcome of older adults with cytogenetically normal A ML (CN-AML) and FLT3 mutations. (PubMed id 21696826)1 Singh H....Attar E.C. (2011)
    325. FLT3-internal tandem duplication and age are the majo r prognostic factors in patients with relapsed acute myeloid leukemia with norm al karyotype. (PubMed id 21242187)1 Wagner K....Krauter J. (2011)
    326. Prognostic value of FLT3 mutations in patients with a cute promyelocytic leukemia treated with all-trans retinoic acid and anthracycl ine monochemotherapy. (PubMed id 21685470)1 BarragA!n E.... . (2011)
    327. Up-regulation of homeodomain genes, DLX1 and DLX2, by FLT3 signaling. (PubMed id 21357706)1 Starkova J....Drabkin H.A. (2011)
    328. FLT3 inhibitors: a story of the old and the new. (PubMed id 21245757)1 Fathi A. and Levis M. (2011)
    329. Sensitive measurement of quantity dynamics of FLT3 in ternal tandem duplication at early time points provides prognostic information. (PubMed id 20693296)1 Chou W.C....Tien H.F. (2011)
    330. PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy. (PubMed id 21589872)1 Zhou J....Chen C.S. (2011)
    331. Clinical impact of FLT3 mutation load in acute promyel ocytic leukemia with t(15;17)/PML-RARA. (PubMed id 21859732)1 Schnittger S....Haferlach T. (2011)
    332. Detection of nucleophosmin and FMS-like tyrosine kina se-3 gene mutations in acute myeloid leukemia. (PubMed id 21245599)1 Pazhakh V....Atashrazm F. (2011)
    333. Presence of FLT3-ITD and high BAALC expression are in dependent prognostic markers in childhood acute myeloid leukemia. (PubMed id 21967978)1 Staffas A....Ehrencrona H. (2011)
    334. FLT3 and NPM1 gene mutations in childhood acute myelob lastic leukemia. (PubMed id 22126574)1 Mukda E....Pakakasama S. (2011)
    335. Wilms' tumor protein and FLT3-internal tandem duplica tion expression in patients with de novo acute myeloid leukemia. (PubMed id 21269566)1 Spassov B.V....Konstantinov S.M. (2011)
    336. FLT3/a88ITD regulates leukaemia cell adhesion through I+4I^1 integrin and Pyk2 signalling. (PubMed id 21114537)1 Katsumi A....Naoe T. (2011)
    337. Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations. (PubMed id 21332708)1 Riccioni R....Testa U. (2011)
    338. c-Cbl and Cbl-b ligases mediate 17-allylaminodemethox ygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with intern al tandem duplication through the ubiquitin proteasome pathway. (PubMed id 21768087)1 Oshikawa G....Miura O. (2011)
    339. Prognostic impact of FLT3-ITD load in NPM1 mutated ac ute myeloid leukemia. (PubMed id 21537333)1 Schnittger S....Haferlach T. (2011)
    340. RUNX1 mutations are frequent in de novo AML with nonc omplex karyotype and confer an unfavorable prognosis. (PubMed id 21148331)1 Schnittger S....Haferlach T. (2011)
    341. p90RSK2 is essential for FLT3-ITD- but dispensable fo r BCR-ABL-induced myeloid leukemia. (PubMed id 21527514)1 Elf S....Kang S. (2011)
    342. Prognostic value of FLT3 mutations among different cy togenetic subgroups in acute myeloid leukemia. (PubMed id 21523727)1 Santos F.P....Borthakur G. (2011)
    343. Attenuation of vaccinia virus by the expression of hu man Flt3 ligand. (PubMed id 20504356)1 Zurkova K....Nemeckova S. (2010)
    344. FLT3 mutation incidence and timing of origin in a pop ulation case series of pediatric leukemia. (PubMed id 20875128)1 Chang P....Wiemels J. (2010)
    345. Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic feat ures. (PubMed id 20354824)1 Chauhan P.S....Kapur S. (2010)
    346. Fms-like tyrosine kinase 3 mutations in childhood acu te leukemias and their association with prognosis. (PubMed id 21133602)1 Karabacak B.H....Tanyeli A. (2010)
    347. Expression of pSTAT5 predicts FLT3 internal tandem du plications in acute myeloid leukemia. (PubMed id 20066533)1 Obermann E.C....Tzankov A. (2010)
    348. Outcome of patients with FLT3-mutated acute myeloid l eukemia in first relapse. (PubMed id 19878996)1 Ravandi F....Beran M. (2010)
    349. High frequencies of simultaneous FLT3-ITD, WT1 and KI T mutations in hematological malignancies with NUP98-fusion genes. (PubMed id 20861915)1 Taketani T....Hayashi Y. (2010)
    350. [Study on the effect of Yiqi Yangyin Recipe and its di fferent assembling on expressions of Flt3 and N-ras in acute myeloid leukemic ce lls]. (PubMed id 20815269)1 Xu R.R....Wang X.L. (2010)
    351. Influence of pharmacogenetic variability on the pharm acokinetics and toxicity of the aurora kinase inhibitor danusertib. (PubMed id 20182906)1 Steeghs N....Guchelaar H.J. (2010)
    352. [FMS-like tyrosine kinase 3 gene mutation in acute my eloid leukemia detected by denaturing PAGE and its clinical significance]. (PubMed id 21176335)1 Ma L....Huang S.Z. (2010)
    353. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts. (PubMed id 20035824)1 Jacobi A....Brenner S. (2010)
    354. [FLT3 and NPM1 gene mutations in patients with acute myeloid leukemias and the impact of FLT3-ITD mutations on the survival of patie nts with a normal karyotype]. (PubMed id 21516736)1 Martynkevich I.S....Abdulkadyrov K.M. (2010)
    355. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells. (PubMed id 20119833)1 StAPlzel F....Thiede C. (2010)
    356. FES kinases are required for oncogenic FLT3 signaling. (PubMed id 20111072)2 Voisset E.... De Sepulveda P. (2010)
    357. Molecular characterization and prognostic significanc e of FLT3 in CML progression. (PubMed id 20031210)1 Kim K.I....Oh J.M. (2010)
    358. FLT3 mutations at diagnosis and relapse in acute myel oid leukemia: cytogenetic and pathologic correlations, including cuplike blast morphology. (PubMed id 20670134)1 McCormick S.R....Reinartz J.J. (2010)
    359. Clinical relevance of FLT3 receptor protein expressio n in Indian patients with acute leukemia. (PubMed id 21114781)1 Vora H.H....Shah P.M. (2010)
    360. Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for gen omic instability and therapy. (PubMed id 20807885)1 Fan J....Rassool F. (2010)
    361. Fms like tyrosine kinase (FLT3) and nucleophosmin 1 ( NPM1) mutations in de novo normal karyotype acute myeloid leukemia (AML). (PubMed id 21338238)1 Dunna N.R....Satti V. (2010)
    362. [JAK2-V617F mutation in patients with myeloproliferat ive neoplasms: association with FLT3-ITD mutation]. (PubMed id 21180092)1 Spasovski V....ColoviA8 M. (2010)
    363. Genomic, immunophenotypic, and NPM1/FLT3 mutational s tudies on 17 patients with normal karyotype acute myeloid leukemia (AML) follow ed by aberrant karyotype AML at relapse. (PubMed id 20875872)1 Wang E.S....Deeb G. (2010)
    364. Combining the FLT3 inhibitor PKC412 and the triterpen oid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with th e internal tandem duplication mutation. (PubMed id 20571062)1 Ahmad R....Stone R. (2010)
    365. Functional characterization of FLT3 receptor signalin g deregulation in acute myeloid leukemia by single cell network profiling (SCNP ). (PubMed id 21048955)1 Rosen D.B....Cesano A. (2010)
    366. Dynamic single-cell network profiles in acute myeloge nous leukemia are associated with patient response to standard induction therap y. (PubMed id 20525753)1 Kornblau S.M....Cesano A. (2010)
    367. Expanding the substantial interactome of NEMO using p rotein microarrays. (PubMed id 20098747)1 Fenner B.J....Prehn J.H. (2010)
    368. FLT3 and NPM1 mutations in Chinese patients with acut e myeloid leukemia and normal cytogenetics. (PubMed id 20872983)1 Wang L....Jin J. (2010)
    369. [Sorafenib in relapsed and refractory FLT3-ITD positi ve acute myeloid leukemia: a novel treatment option]. (PubMed id 20740398)1 Metzelder S.K....Burchert A. (2010)
    370. Prognostic significance of FLT3 internal tandem duplic ation in egyptian patients with acute myeloid leukemia with normal or favorable risk cytogenetics. (PubMed id 23082484)1 Shahin D....Ebrahim M.A. (2010)
    371. Large-scale proteomics analysis of the human kinome. (PubMed id 19369195)2 Oppermann F.S.... Daub H. (2009)
    372. Molecular variability of FLT3/ITD mutants and their i mpact on the differentiation program of 32D cells: implications for the biologi cal properties of AML blasts. (PubMed id 19181379)1 Pekova S....Prucha M. (2009)
    373. A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survival. (PubMed id 19438505)1 Masson K....RAPnnstrand L. (2009)
    374. Gene-centric association signals for lipids and apoli poproteins identified via the HumanCVD BeadChip. (PubMed id 19913121)1 Talmud P.J.... . (2009)
    375. Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. (PubMed id 18483393)1 Breitenbuecher F....Fischer T. (2009)
    376. Transcriptional control of Flt3 ligand targeted by fl uorouracil-induced Egr-1 promoter in hematopoietic damage. (PubMed id 19765320)1 Du N....Hao Y. (2009)
    377. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and infe rior outcome. (PubMed id 19602710)1 Kayser S....DAPhner K. (2009)
    378. [Regulation of Wnt/beta-catenin signaling by receptor tyrosine kinases in hematological malignancy] (PubMed id 19915372)1 Kajiguchi T. (2009)
    379. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of dis tinct leukemogenesis involving monocyte differentiation pathway. (PubMed id 19296110)1 Koh Y....Kim B.K. (2009)
    380. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). (PubMed id 19279329)1 Schneider F....Spiekermann K. (2009)
    381. Survivin mediates aberrant hematopoietic progenitor c ell proliferation and acute leukemia in mice induced by internal tandem duplica tion of Flt3. (PubMed id 19411632)1 Fukuda S....Pelus L.M. (2009)
    382. Acute myeloid leukemia with NUP98-HOXC13 fusion and F LT3 internal tandem duplication mutation: case report and literature review. (PubMed id 19665070)1 TosiA8 N....PavloviA8 S. (2009)
    383. [Expression of FLT3 internal tandem duplication in pe diatric patients with acute myeloid leukemia and its correlation with multidrug resistance]. (PubMed id 19236740)1 Zhao J.N....Wang Z. (2009)
    384. Impaired S-phase arrest in acute myeloid leukemia cel ls with a FLT3 internal tandem duplication treated with clofarabine. (PubMed id 19934300)1 Seedhouse C....Pallis M. (2009)
    385. Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality. (PubMed id 19204327)1 Schmidt-Arras D....BAPhmer F.D. (2009)
    386. Prevalence of FMS-like tyrosine kinase 3/internal tan dem duplication (FLT3/ITD+) in de novo acute myeloid leukemia patients categori zed according to cytogenetic risk. (PubMed id 19466291)1 Krum E.A....Chauffaille M.d.e. .L. (2009)
    387. Single institute study of FLT3 mutation in acute myel oid leukemia with near tetraploidy in Serbia. (PubMed id 19700852)1 JurisiA8 V....ColoviA8 M. (2009)
    388. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. (PubMed id 18192505)1 Sallmyr A....Rassool F. (2008)
    389. Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD. (PubMed id 17972951)1 Hou H.A....Tien H.F. (2008)
    390. Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients. (PubMed id 18464120)1 Breccia M....Alimena G. (2008)
    391. An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. (PubMed id 18309032)1 Bullinger L....Pollack J.R. (2008)
    392. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. (PubMed id 18184863)1 Weisberg E....Griffin J.D. (2008)
    393. Abnormal localization and accumulation of FLT3-ITD, a mutant receptor tyrosine kinase involved in leukemogenesis. (PubMed id 18303245)1 Koch S....Thiede C. (2008)
    394. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. (PubMed id 18987736)2 Ley T.J.... Wilson R.K. (2008)
    395. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation. (PubMed id 18343790)1 Rausei-Mills V....Huang Q. (2008)
    396. Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic antitumor immunity. (PubMed id 19016763)1 Saito T....Tahara H. (2008)
    397. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. (PubMed id 17965322)1 Bacher U....Schnittger S. (2008)
    398. Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease. (PubMed id 17268528)1 Baldwin B.R....Small D. (2007)
    399. [Flt-3/ITD mutation in pediatric leukemia and its cli nical significance] (PubMed id 17222369)1 Wang J....Gang Y. (2007)
    400. Four novel point mutations in exons 12, 13, and 14 of the FLT3 gene. (PubMed id 16949153)1 Syampurnawati M....Hayashi Y. (2007)
    401. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. (PubMed id 17128418)1 Siendones E....Lopez-Pedrera C. (2007)
    402. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia. (PubMed id 17579862)1 Colovic N....Pavlovic S. (2007)
    403. Patterns of somatic mutation in human cancer genomes. (PubMed id 17344846)2 Greenman C.... Stratton M.R. (2007)
    404. Cytoplasmic localization of phosphorylated STAT5 in human acute myeloid leukemia is inversely correlated with Flt3-ITD. (PubMed id 17881646)1 Bunting K.D....Hsi E.D. (2007)
    405. HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression. (PubMed id 17056111)1 Syampurnawati M....Hayashi Y. (2007)
    406. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. (PubMed id 17312001)1 Bornhauser M....Thiede C. (2007)
    407. Cell-free bead-based detection of total and phosphorylated proteins in plasma and cell lysates: detection of FLT3. (PubMed id 18605083)1 Chan H.E....Albitar M. (2007)
    408. Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. (PubMed id 17105820)1 Irish J.M....Gjertsen B.T. (2007)
    409. Transcriptional signals of T-cell and corticosteroid-sensitive genes are associated with future acute cellular rejection in cardiac allografts. (PubMed id 18096476)1 Mehra M.R....Eisen H.J. (2007)
    410. The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. (PubMed id 16990788)1 Ponziani V....Vannucchi A.M. (2006)
    411. Flk2+ myeloid progenitors are the main source of Langerhans cells. (PubMed id 16263793)1 Mende I....Merad M. (2006)
    412. Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. (PubMed id 16517725)1 Curtin J.F....Castro M.G. (2006)
    413. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. (PubMed id 16368883)1 Stirewalt D.L....Radich J.P. (2006)
    414. FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. (PubMed id 16809615)1 Pollard J.A....Meshinchi S. (2006)
    415. FLT3 mutations in acute myeloid leukemia. (PubMed id 16502586)1 Kiyoi H. and Naoe T. (2006)
    416. Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6. (PubMed id 15978940)1 Takahashi S....Kaku M. (2005)
    417. Neurotrophin-3 and FLT3 tyrosine kinase receptor in perinatal life. (PubMed id 15770067)1 Malamitsi-Puchner A....Vrachnis N. (2005)
    418. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. (PubMed id 15797998)1 Levis M....Small D. (2005)
    419. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. (PubMed id 15769897)1 Choudhary C....Serve H. (2005)
    420. Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis. (PubMed id 15242879)1 Chung K.Y....Moore M.A. (2005)
    421. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. (PubMed id 15650056)1 Tickenbrock L....Serve H. (2005)
    422. Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia. (PubMed id 15921740)1 Scholl S....Hoffken K. (2005)
    423. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype. (PubMed id 15674343)1 Neben K....Schoch C. (2005)
    424. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). (PubMed id 15489334)2 Gerhard D.S....Malek J. (2004)
    425. Synergistic effect of SU11248 with cytarabine or daun orubicin on FLT3 ITD-positive leukemic cells. (PubMed id 15304385)7 Yee K.W....Heinrich M.C. (2004)
    426. Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy. (PubMed id 15289019)1 Tiesmeier J....Verbeek W. (2004)
    427. The DNA sequence and analysis of human chromosome 13. (PubMed id 15057823)2 Dunham A.... Ross M.T. (2004)
    428. Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples. (PubMed id 14977832)1 Shih L.Y....Tang C.C. (2004)
    429. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. (PubMed id 15178581)1 Jiang J....Sellers W.R. (2004)
    430. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. (PubMed id 12969963)1 Zheng R....Small D. (2004)
    431. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. (PubMed id 14981546)1 Scheijen B....Griffin J.D. (2004)
    432. SU11248 is a novel FLT3 tyrosine kinase inhibitor wit h potent activity in vitro and in vivo. (PubMed id 12531805)7 O'Farrell A.M....Cherrington J.M. (2003)
    433. FLT3 and its role in the pathogenesis of acute myeloid leukaemia. (PubMed id 12691136)1 Reilly J.T. (2003)
    434. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. (PubMed id 12816873)1 Zwaan C.M....Griesinger F. (2003)
    435. FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia. (PubMed id 12926083)1 Galimberti S....Petrini M. (2003)
    436. Acute myelogenous leukemia with internal tandem duplication of the Flt3 gene appearing or altering at the time of relapse: a report of two cases. (PubMed id 12481903)1 Hovland R....Bruserud O. (2002)
    437. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. (PubMed id 12239146)1 Shih L.Y....Hsu H.C. (2002)
    438. TTD: Therapeutic Target Database. (PubMed id 11752352)7 Chen X....Chen Y.Z. (2002)
    439. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. (PubMed id 12477932)1 Strausberg R.L....Marra M.A. (2002)
    440. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. (PubMed id 12060771)1 Kelly L.M....Gilliland D.G. (2002)
    441. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations. (PubMed id 12393674)1 Zheng R....Small D. (2002)
    442. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. (PubMed id 12070009)1 Schnittger S....Hiddemann W. (2002)
    443. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. (PubMed id 12384447)1 Spiekermann K....Schnittger S. (2002)
    444. Flt3/Flk-2-ligand in synergy with thrombopoietin delays megakaryocyte development and increases the numbers of megakaryocyte progenitor cells in serum-free cultures initiated with CD34+ cells. (PubMed id 11983110)1 Sigurjonsson O.E....Guomundsson S. (2002)
    445. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. (PubMed id 12036858)1 Thiede C....Illmer T. (2002)
    446. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. (PubMed id 11535508)1 Kottaridis P.D....Linch D.C. (2001)
    447. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. (PubMed id 11091200)1 Abu-Duhier F.M....Reilly J.T. (2000)
    448. Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. (PubMed id 10022833)1 De Sepulveda P....Rottapel R. (1999)
    449. SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. (PubMed id 10482988)1 Marchetto S....Rosnet O. (1999)
    450. Fiz1, a novel zinc finger protein interacting with the receptor tyrosine kinase Flt3. (PubMed id 10409713)1 Wolf I. and Rohrschneider L.R. (1999)
    451. The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells. (PubMed id 9614102)1 Lavagna-Sevenier C....Rosnet O. (1998)
    452. Structure-function analysis of FLT3 ligand-FLT3 receptor interactions using a rapid functional screen. (PubMed id 9651358)1 Graddis T.J....McGrew J.T. (1998)
    453. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. (PubMed id 7505204)1 Lyman S.D....Splett R.R. (1993)
    454. Familial Acute Myeloid Leuke mia (AML) with Mutated CEBPA (PubMed id 20963938)1 Klein R.D. and Marcucci G. (1993)
    455. Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. (PubMed id 7692230)1 Dosil M....Lemischka I.R. (1993)
    456. (PubMed id 19727728)4 
    457. (PubMed id 16627759)2 
    458. Detailed analysis of FLT3 expression levels in acute myeloid leukemia. (PubMed id 16330434)9 Kuchenbauer F....Schnittger S. (2005)
    459. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. (PubMed id 11455967)9 Tse K.F....Small D. (2001)
    460. Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. (PubMed id 9207445)9 Rappold I....Buhring H.J. (1997)
    461. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. (PubMed id 16868253)9 Knapper S....Burnett A.K. (2006)
    462. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. (PubMed id 14604973)9 Ozeki K....Naoe T. (2004)
    463. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. (PubMed id 10691863)9 Fenski R....Serve H. (2000)
    464. Expression of Flt3 and c-kit during growth and maturation of human CD34+CD38- cells. (PubMed id 10340408)9 Xiao M....Dooley D.C. (1999)
    465. Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML). (PubMed id 17156841)9 Ravandi F....Albitar M. (2007)
    466. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. (PubMed id 15374878)9 Brown P....Small D. (2005)
    467. Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT). (PubMed id 17233551)9 Doubek M....Indrak K. (2007)
    468. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. (PubMed id 15956279)9 Stam R.W....Pieters R. (2005)
    469. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. (PubMed id 15498859)9 Kim K.T....Small D. (2005)
    470. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. (PubMed id 12406902)9 Spiekermann K....Hiddemann W. (2003)
    471. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. (PubMed id 8562934)9 Carow C.E....Small D. (1996)
    472. KW-2449, a novel multikinase inhibitor, suppresses th e growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translo cation. (PubMed id 19541823)9 Shiotsu Y....Naoe T. (2009)
    473. [In vitro transcription synthesis and effects of FLT3 targeted short hairpin RNA] (PubMed id 17708815)9 Lu J....Wang J.R. (2007)
    474. Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. (PubMed id 17330105)9 Furukawa Y....Kano Y. (2007)
    475. FLT3 overexpression in acute promyelocytic leukemia patients without detectable FLT3-ITD or codon 835-836 mutations: a pilot study. (PubMed id 16619525)9 Lilakos K....Pangalis G.A. (2006)
    476. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway. (PubMed id 16034464)9 Yao Q....Kersey J.H. (2005)
    477. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. (PubMed id 14555522)9 Yao Q....Kersey J.H. (2003)
    478. Identification of fetal liver tyrosine kinase 3 (flt3) ligand domain required for receptor binding and function using naturally occurring ligand isoforms. (PubMed id 11120823)9 Mwangi W....Palmer G.H. (2000)
    479. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. (PubMed id 20007803)9 Pratz K.W....Levis M. (2010)
    480. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis. (PubMed id 19946262)9 Kojima K....Nakakuma H. (2010)
    481. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. (PubMed id 19029442)9 Pratz K.W....Levis M. (2009)
    482. Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. (PubMed id 18452067)9 Pratz K. and Levis M. (2008)
    483. RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. (PubMed id 15585651)9 Walters D.K....Druker B.J. (2005)
    484. High expression but no internal tandem duplication of FLT3 in normal hematopoietic cells. (PubMed id 10505320)9 Ishii E....Miyazaki S. (1999)
    485. RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias. (PubMed id 18977066)9 Usher S.G....Blackwood L. (2009)
    486. [Effects of FMS-like tyrosine kinase 3 targeted RNA interference on proliferation and apoptosis of acute monocytic leukemia cell line THP-1] (PubMed id 18021537)9 Lu J....Xu P.R. (2007)
    487. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. (PubMed id 17332306)9 Yao Q....Kersey J. (2007)
    488. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. (PubMed id 17554384)9 Kohl T.M....Spiekermann K. (2007)
    489. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. (PubMed id 16105978)9 Gale R.E....Grimwade D. (2005)
    490. Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. (PubMed id 15256420)9 Clark J.J....Gilliland D.G. (2004)
    491. FLT3 mutations in acute myeloid leukemia cell lines. (PubMed id 12529668)9 Quentmeier H....Drexler H.G. (2003)
    492. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. (PubMed id 12515727)9 Sohal J....Kogan S.C. (2003)
    493. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. (PubMed id 12357354)9 Tse K.F....Small D. (2002)
    494. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. (PubMed id 19467916)9 Weisberg E....Griffin J.D. (2009)
    495. Cloning and expression profile of FLT3 gene during progenitor cell-dependent liver regeneration. (PubMed id 18031378)9 Aydin I.T....Akcali K.C. (2007)
    496. Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. (PubMed id 16722630)9 Mahboobi S....Dove S. (2006)
    497. FLT3 mutations: biology and treatment. (PubMed id 17124058)9 Small D. (2006)
    498. FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targeting. (PubMed id 16631251)9 Giles F.J. (2006)
    499. [Analysis of Flt-3 expression and Flt-3/ITD mutation in acute myeloid leukemia cells] (PubMed id 16800917)9 Wang Y.L....Wang J. (2006)
    500. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. (PubMed id 16857987)9 Levis M....Small D. (2006)
    501. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. (PubMed id 16857985)9 Knapper S....Small D. (2006)
    502. Presence of FLT3 mutations does not impair stem cell mobilization and feasibility of autologous peripheral blood stem cell transplantation in acute myeloid leukemia. (PubMed id 16920565)9 Ferrara F....Pane F. (2006)
    503. Clinical significance of FLT3 in leukemia. (PubMed id 16146837)9 Kiyoi H....Ozekia K. (2005)
    504. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. (PubMed id 14726387)9 Smith B.D....Small D. (2004)
    505. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. (PubMed id 15158089)9 O'Farrell A.M....Giles F.J. (2004)
    506. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. (PubMed id 12393388)9 Frohling S....Dohner K. (2002)
    507. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. (PubMed id 10216104)9 Kiyoi H....Ueda R. (1999)
    508. Flt3 ligand can promote survival and macrophage development without proliferation in myeloid progenitor cells. (PubMed id 10210324)9 Nicholls S.E....Whetton A.D. (1999)
    509. Expression of the FLT3 gene in human leukemia-lymphoma cell lines. (PubMed id 8182945)9 DaSilva N....Drexler H.G. (1994)
    510. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. (PubMed id 1384791)9 Birg F....Birnbaum D. (1992)
    511. Molecular analysis of PDGFRA and PDGFRB genes by rapid single-strand conformation polymorphism (SSCP) in patients with core-binding factor leukaemias with KIT or FLT3 mutation. (PubMed id 19035305)9 Trojani A....Morra E. (2008)
    512. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma. (PubMed id 17941064)9 Shimada A....Hayashi Y. (2008)
    513. Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin. (PubMed id 17827387)9 Barry E.V....Gilliland D.G. (2007)
    514. FLT3 inhibition in acute myeloid leukaemia. (PubMed id 17655729)9 Knapper S. (2007)
    515. Sensitivity toward sorafenib and sunitinib varies bet ween different activating and drug-resistant FLT3-ITD mutations. (PubMed id 17889720)9 Kancha R.K....Duyster J. (2007)
    516. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. (PubMed id 16902153)9 DeAngelo D.J....Heinrich M.C. (2006)
    517. ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells. (PubMed id 16473406)9 Scholl S....HAPffken K. (2006)
    518. FLT3 and acute myelogenous leukemia: biology, clinical significance and therapeutic applications. (PubMed id 16250847)9 Advani A.S. (2005)
    519. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. (PubMed id 15345597)9 Stone R.M....Griffin J.D. (2005)
    520. The roles of FLT3 in hematopoiesis and leukemia. (PubMed id 12176867)9 Gilliland D.G. and Griffin J.D. (2002)
    521. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. (PubMed id 12010785)9 Levis M....Small D. (2002)
    522. Coduplication of the MLL and FLT3 genes in patients with acute myeloid leukemia. (PubMed id 11319806)9 Jamal R....Hayashi Y. (2001)
    523. Expansion of megakaryocyte precursors and stem cells from umbilical cord blood CD34+ cells in collagen and liquid culture media. (PubMed id 11454314)9 Shaw P.H....Kletzel M. (2001)
    524. The FLT3 inhibitor tandutinib (formerly MLN518) has s equence-independent synergistic effects with cytarabine and daunorubicin. (PubMed id 19625780)9 Schittenhelm M.M....Heinrich M.C. (2009)
    525. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. (PubMed id 19064725)9 NordigAYrden A....JAPnsson J.I. (2009)
    526. Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. (PubMed id 18820131)9 Weisberg E....Griffin J.D. (2008)
    527. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591. (PubMed id 18628457)9 Vempati S....Spiekermann K. (2008)
    528. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. (PubMed id 17379095)9 Moore M.A....Morrone G. (2007)
    529. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. (PubMed id 17209055)9 Shankar D.B....Glaser K.B. (2007)
    530. The effect of brief exercise on circulating CD34+ stem cells in early and late pubertal boys. (PubMed id 17515877)9 Zaldivar F....Cooper D.M. (2007)
    531. Flt3 is dispensable to the Hoxa9/Meis1 leukemogenic cooperation. (PubMed id 17202314)9 Morgado E....Lavau C. (2007)
    532. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. (PubMed id 17066094)9 Seedhouse C.H....Russell N.H. (2006)
    533. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. (PubMed id 15242881)9 Griswold I.J....Deininger M.W. (2004)
    534. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q). (PubMed id 15257941)9 Fidler C....Boultwood J. (2004)
    535. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. (PubMed id 12780793)9 Care R.S....Reilly J.T. (2003)
    536. Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis. (PubMed id 12580961)9 Abu-Duhier F.M....Reilly J.T. (2003)
    537. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. (PubMed id 11753614)9 Birkenkamp K.U....Vellenga E. (2001)
    538. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. (PubMed id 10720129)9 Zhao M....Naoe T. (2000)
    539. FLT3 ligand preserves the uncommitted CD34+CD38- progenitor cells during cytokine prestimulation for retroviral transduction. (PubMed id 11091493)9 Nielsen S.D....Hansen J.E. (2000)
    540. ITD- and FL-induced FLT3 signal transduction leads to increased C/EBPbeta-LIP expression and LIP/LAP ratio by different signalling m odules. (PubMed id 19958352)9 Haas S.C....Brand K. (2010)
    541. Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10. (PubMed id 20127944)9 Youssoufian H....Li Y. (2010)
    542. Lestaurtinib, a multitargeted tyrosine kinase inhibit or: from bench to bedside. (PubMed id 20141349)9 Shabbir M. and Stuart R. (2010)
    543. Analysis of factors that affect in vitro chemosensiti vity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. (PubMed id 19776761)9 Jawad M....Pallis M. (2010)
    544. Dasatinib inhibits the growth of molecularly heteroge neous myeloid leukemias. (PubMed id 20145167)9 Guerrouahen B.S....Corey S.J. (2010)
    545. Fms-like tyrosine kinase 3 ligand increases a lung DC subset with regulatory properties in allergic airway inflammation. (PubMed id 19348927)9 Shao Z....Agrawal D.K. (2009)
    546. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. (PubMed id 19734451)9 Bandi S.R....Sargin B. (2009)
    547. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. (PubMed id 19318574)9 von Bubnoff N....Duyster J. (2009)
    548. Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication. (PubMed id 18341639)9 Mead A.J....Linch D.C. (2008)
    549. FIP1L1-PDGFRalpha alone or with other genetic abnorma lities reveals disease progression in chronic eosinophilic leukemia but good re sponse to imatinib. (PubMed id 18706197)9 Wang L.N....Chen S.J. (2008)
    550. The FLT3 inhibitor PKC412 in combination with cytosta tic drugs in vitro in acute myeloid leukemia. (PubMed id 17960382)9 MAPllgAYrd L....Lehmann S. (2008)
    551. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. (PubMed id 18230792)9 Zhang W....Andreeff M. (2008)
    552. Targeting FLT3 for the treatment of leukemia. (PubMed id 18760705)9 Small D. (2008)
    553. Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia. (PubMed id 18668305)9 Tickenbrock L....Serve H. (2008)
    554. Mutations of GATA1, FLT3, MLL-partial tandem duplication, NRAS, and RUNX1 genes are not found in a 7-year-old Down syndrome patient with acute myeloid leukemia (FAB-M2) having a good prognosis. (PubMed id 18068539)9 Kawamura M....Hayashi Y. (2008)
    555. Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment. (PubMed id 18509353)9 Mony U....Pallis M. (2008)
    556. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications. (PubMed id 18175263)9 Cheng Y. and Paz K. (2008)
    557. Potentiation of antileukemic therapies by Smac mimeti c, LBW242: effects on mutant FLT3-expressing cells. (PubMed id 17620426)9 Weisberg E....Griffin J.D. (2007)
    558. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. (PubMed id 17356133)9 Choudhary C....Serve H. (2007)
    559. Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. (PubMed id 17121903)9 Wetzler M....Baumann H. (2006)
    560. Expression of c-kit, Flk-1, and Flk-2 receptors in benign and malignant tumors of follicular epithelial origin. (PubMed id 16570574)9 Kung S.P....Wu C.W. (2006)
    561. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. (PubMed id 16761019)9 Vu H.A....Sato Y. (2006)
    562. Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. (PubMed id 16757428)9 Kiyoi H. and Naoe T. (2006)
    563. From kinases to cancer: leakiness, loss of autoinhibition and leukemia. (PubMed id 16582613)9 Reindl C. and Spiekermann K. (2006)
    564. Developing target therapy against oncogenic tyrosine kinase in myeloid maliganacies. (PubMed id 17076649)9 Naoe T. (2006)
    565. Molecular profile and partial functional analysis of novel endothelial cell-derived growth factors that regulate hematopoiesis. (PubMed id 16373696)9 Chute J.P....Lin S. (2006)
    566. Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours. (PubMed id 16785193)9 Sihto H....Isola J. (2006)
    567. Frequency of RAS gene mutation and its cooperative genetic events in Southeast Asian adult acute myeloid leukemia. (PubMed id 16573741)9 Auewarakul C.U....Tocharoentanaphol C. (2006)
    568. Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication. (PubMed id 17050201)9 Takahashi S....Kaku M. (2006)
    569. Circulating haemopoietic and endothelial progenitor cells are decreased in COPD. (PubMed id 16507853)9 Palange P....Bonsignore M.R. (2006)
    570. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. (PubMed id 16585210)9 Adam M....Schwaller J. (2006)
    571. Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients. (PubMed id 16424869)9 Roumier C....Preudhomme C. (2006)
    572. Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes. (PubMed id 16648484)9 Wang G.G....Kamps M.P. (2006)
    573. The FLT3 Internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. (PubMed id 16103085)9 Yang X....Stone R. (2005)
    574. Roles of tyrosine residues 845, 892 and 922 in constitutive activation of murine FLT3 kinase domain mutant. (PubMed id 16091740)9 Ishiko J....Kanakura Y. (2005)
    575. Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia. (PubMed id 15976757)9 Scholl S....HAPffken K. (2005)
    576. Signal transduction of oncogenic Flt3. (PubMed id 16146838)9 Choudhary C....Serve H. (2005)
    577. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. (PubMed id 16025155)9 Schessl C....Buske C. (2005)
    578. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice. (PubMed id 15735040)9 Piloto O....Small D. (2005)
    579. Delineation and molecular characterization of acute myeloid leukemia patients with coduplication of FLT3 and MLL. (PubMed id 16104873)9 Olesen L.H....Hokland P. (2005)
    580. Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus. (PubMed id 15755900)9 Wang G.G....Kamps M.P. (2005)
    581. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. (PubMed id 15251987)9 Lacayo N.J....Dahl G.V. (2004)
    582. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. (PubMed id 14976243)9 Mohi M.G....Neel B.G. (2004)
    583. [Expansion of CIK/NK cells from cord blood by using different combinations of stem cell factor, FLT3 ligand and interleukin 2, 7, 15 in vitro] (PubMed id 15228665)9 Li Y....Zhou D.H. (2004)
    584. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. (PubMed id 14726504)9 Frohling S....Dohner K. (2004)
    585. Molecular events in follicular thyroid tumors. (PubMed id 16209039)9 Kroll T.G. (2004)
    586. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. (PubMed id 15105287)9 Li Y....Hicklin D.J. (2004)
    587. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. (PubMed id 14984498)9 Stirewalt D.L....Radich J.P. (2004)
    588. Ex vivo expansion of megakaryocyte precursors from umbilical cord blood CD34 cells in a closed liquid culture system. (PubMed id 12652464)9 Shaw P.H....Corey S.J. (2003)
    589. Preferential ex vivo expansion of megakaryocytes from human cord blood CD34+-enriched cells in the presence of thrombopoietin and limiting amounts of stem cell factor and Flt-3 ligand. (PubMed id 12804177)9 Proulx C....Lemieux R. (2003)
    590. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). (PubMed id 12815052)9 Murata K....Kitamura T. (2003)
    591. FLT3-TKD mutation in childhood acute myeloid leukemia. (PubMed id 12750701)9 Liang D.C....Chang W.H. (2003)
    592. Flow cytometric measurement of phosphorylated STAT5 in AML: lack of specific association with FLT3 internal tandem duplications. (PubMed id 12804638)9 Pallis M....Russell N. (2003)
    593. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. (PubMed id 12796379)9 Spiekermann K....Hiddemann W. (2003)
    594. SU5416 and SU5614 inhibit kinase activity of wild-typ e and mutant FLT3 receptor tyrosine kinase. (PubMed id 12351406)9 Yee K.W....Heinrich M.C. (2002)
    595. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. (PubMed id 12145695)9 Minami Y....Naoe T. (2002)
    596. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. (PubMed id 11468194)9 Levis M....Small D. (2001)
    597. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy. (PubMed id 11753604)9 Christiansen D.H. and Pedersen-Bjergaard J. (2001)
    598. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. (PubMed id 11342433)9 Majka M....Ratajczak M.Z. (2001)
    599. Efficient retrovirus-mediated transduction of primitive human peripheral blood progenitor cells in stroma-free suspension culture. (PubMed id 11406763)9 Berger F....Licht T. (2001)
    600. Efficient ex vivo generation of human dendritic cells from mobilized CD34+ peripheral blood progenitors. (PubMed id 11721965)9 Ohishi K....Shiku H. (2001)
    601. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. (PubMed id 10974037)9 Zhang S....Broxmeyer H.E. (2000)
    602. Flow cytometric detection of growth factor receptors in autografts and analysis of growth factor concentrations in autologous stem cell transplantation: possible significance for platelet recovery. (PubMed id 11019842)9 Schiodt I....Johnsen H.E. (2000)
    603. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. (PubMed id 10233379)9 Xu F....Hayashi Y. (1999)
    604. Optimization of retroviral gene transduction of mobilized primitive hematopoietic progenitors by using thrombopoietin, Flt3, and Kit ligands and RetroNectin culture. (PubMed id 10446914)9 Murray L....Hill B. (1999)
    605. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan. (PubMed id 10049058)9 Iwai T....Fujimoto T. (1999)
    606. Thrombopoietin, flt3, and kit ligands together suppress apoptosis of human mobilized CD34+ cells and recruit primitive CD34+ Thy-1+ cells into rapid division. (PubMed id 10378891)9 Murray L.J....Hill B.L. (1999)
    607. Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. (PubMed id 9731044)9 Kiem H.P....Miller A.D. (1998)
    608. Synergistic action of Flt3 and gp130 signalings in hu man hematopoiesis. (PubMed id 9373247)9 Ebihara Y....Nakahata T. (1997)
    609. Thrombopoietin augments ex vivo expansion of human cord blood-derived hematopoietic progenitors in combination with stem cell factor and flt3 ligand. (PubMed id 9096693)9 Ohmizono Y....Sonoda Y. (1997)
    610. Haemopoietic growth factor tyrosine kinase receptor expression profiles in normal haemopoiesis. (PubMed id 8759881)9 Visser M....Landegent J.E. (1996)
    611. Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts. (PubMed id 8847893)9 Stacchini A....Piacibello W. (1996)
    612. Rapid isolation of cell-type-specific protein tyrosine kinases by degenerate polymerase chain reaction combined with differential hybridization technique. (PubMed id 7669053)9 Kim S.J....Terada M. (1995)
    613. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. (PubMed id 20147976)9 Moore A.S....Pearson A.D. (2010)
    614. Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. (PubMed id 20416083)9 Zhu X....Liu D. (2010)
    615. The role of molecular tests in acute myelogenous leuk emia treatment decisions. (PubMed id 20425404)9 Motyckova G. and Stone R.M. (2010)
    616. Functional characterization of high levels of meningi oma 1 as collaborating oncogene in acute leukemia. (PubMed id 20072157)9 Liu T....Schwaller J. (2010)
    617. Favorable prognostic impact of NPM1 mutations in olde r patients with cytogenetically normal de novo acute myeloid leukemia and assoc iated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B s tudy. (PubMed id 20026798)9 Becker H....Bloomfield C.D. (2010)
    618. Antiangiogenic drugs in oncology: a focus on drug saf ety and the elderly - a mini-review. (PubMed id 19940466)9 Boehm S....Joerger M. (2010)
    619. Micro-RNAs and copy number changes: new levels of gen e regulation in acute myeloid leukemia. (PubMed id 19822134)9 Larson R.A. (2010)
    620. A randomized phase I clinical and biologic study of t wo schedules of sorafenib in patients with myelodysplastic syndrome or acute my eloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Gr oup Study. (PubMed id 20109071)9 Crump M....Seymour L. (2010)
    621. Targeted therapy in haematological malignancies. (PubMed id 20041451)9 Hamilton A....Holyoake T.L. (2010)
    622. Design and synthesis of new anticancer pyrimidines wi th multiple-kinase inhibitory effect. (PubMed id 20471842)9 El-Deeb I.M. and Lee S.H. (2010)
    623. Copy neutral loss of heterozygosity: a novel chromoso mal lesion in myeloid malignancies. (PubMed id 20107230)9 O'Keefe C....Maciejewski J.P. (2010)
    624. Bench to bedside targeting of FLT3 in acute leukemia. (PubMed id 20370649)9 Pratz K.W. and Levis M.J. (2010)
    625. Colony stimulating factor-1 receptor as a target for small molecule inhibitors. (PubMed id 20156689)9 Mashkani B....Ashman L.K. (2010)
    626. Modeling interactions between leukemia-specific chrom osomal changes, somatic mutations, and gene expression patterns during progress ion of core-binding factor leukemias. (PubMed id 19908318)9 Jones D....Kantarjian H. (2010)
    627. Acute myeloid leukemia with biallelic CEBPA gene muta tions and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. (PubMed id 20038735)9 Dufour A....Spiekermann K. (2010)
    628. Single nucleotide polymorphism in the mutational hots pot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. (PubMed id 20038731)9 Damm F....Krauter J. (2010)
    629. Sorafenib. (PubMed id 20072831)9 Hasskarl J. (2010)
    630. Sunitinib malate is active against human urothelial c arcinoma and enhances the activity of cisplatin in a preclinical model. (PubMed id 18534874)9 Sonpavde G....Lerner S.P. (2009)
    631. Biological activity of dendritic cells generated from cord blood CD34+ hematopoietic progenitors in IL-7- and IL-13-conditioned cultures. (PubMed id 19219529)9 Mytar B....Zembala M. (2009)
    632. Long-term efficacy and safety of all-trans retinoic a cid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leuke mia. (PubMed id 19225113)9 Hu J....Chen Z. (2009)
    633. Sunitinib: a multitargeted receptor tyrosine kinase i nhibitor in the era of molecular cancer therapies. (PubMed id 19894779)9 Papaetis G.S. and Syrigos K.N. (2009)
    634. Detection of a CD4+CD8-CD3- cell subpopulation during the differentiation of cord blood CD34+ cells into T cells in vitro. (PubMed id 19479205)9 Jin J.G....Chen H. (2009)
    635. Suppression of CXCL12 production by bone marrow osteo blasts is a common and critical pathway for cytokine-induced mobilization. (PubMed id 19141863)9 Christopher M.J....Link D.C. (2009)
    636. Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia. (PubMed id 18726096)9 Ruan G.R....Huang X.J. (2009)
    637. Derivation of functional mature neutrophils from huma n embryonic stem cells. (PubMed id 19321863)9 Yokoyama Y....Chiba S. (2009)
    638. Targeting the leukemia microenvironment by CXCR4 inhi bition overcomes resistance to kinase inhibitors and chemotherapy in AML. (PubMed id 18955566)9 Zeng Z....Konopleva M. (2009)
    639. Plasma levels of FL and SDF-1 and expression of FLT-3 and CXCR4 on CD34+ cells assessed pre and post hematopoietic stem cell mobiliz ation in patients with hematologic malignancies and in healthy donors. (PubMed id 19380254)9 Cecyn K.Z....Oliveira J.S. (2009)
    640. Investigational drugs targeting FLT3 for leukemia. (PubMed id 19671038)9 Ustun C....Bhalla K.N. (2009)
    641. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. (PubMed id 19569254)9 Rau R. and Brown P. (2009)
    642. Mislocalized activation of oncogenic RTKs switches do wnstream signaling outcomes. (PubMed id 19854140)9 Choudhary C....Serve H. (2009)
    643. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). (PubMed id 19654408)9 Zarrinkar P.P....Bhagwat S.S. (2009)
    644. Tyrosine kinase inhibitors - a review on pharmacology , metabolism and side effects. (PubMed id 19689244)9 Hartmann J.T....Lipp H.P. (2009)
    645. [Molecular markers related to prognosis of acute myel oid leukemia-review] (PubMed id 19698266)9 Sun C....Sheng Y.F. (2009)
    646. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{ 4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. (PubMed id 19754199)9 Chao Q....Bhagwat S.S. (2009)
    647. Diverse T-cell differentiation potentials of human fe tal thymus, fetal liver, cord blood and adult bone marrow CD34 cells on lentivi ral Delta-like-1-modified mouse stromal cells. (PubMed id 19740310)9 Patel E....Chang L.J. (2009)
    648. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. (PubMed id 18927438)9 Kearney L....Greaves M. (2009)
    649. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. (PubMed id 19276253)9 Reindl C....Spiekermann K. (2009)
    650. Myelosuppression and kinase selectivity of multikinas e angiogenesis inhibitors. (PubMed id 19844230)9 Kumar R....King A.G. (2009)
    651. Inhibition of tumor cell growth, invasion, and metast asis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF recept or tyrosine kinases. (PubMed id 19808973)9 Qian F....Joly A.H. (2009)
    652. Molecular stratification model for prognosis in cytog enetically normal acute myeloid leukemia. (PubMed id 19398719)9 SantamarA-a C.M....Gonzalez M. (2009)
    653. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. (PubMed id 19490647)9 Gregory T.K....Tse W. (2009)
    654. High-efficiency production of subculturable vascular endothelial cells from feeder-free human embryonic stem cells without cell-sort ing technique. (PubMed id 20025522)9 Nakahara M....Saeki K. (2009)
    655. Prognostic importance of MN1 transcript levels, and b iologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B s tudy. (PubMed id 19451432)9 Langer C....Bloomfield C.D. (2009)
    656. Genes predictive of outcome and novel molecular class ification schemes in adult acute myeloid leukemia. (PubMed id 20306246)9 Verhaak R.G. and Valk P.J. (2009)
    657. [Molecular mechanisms in the development of acute mye loid leukemia] (PubMed id 19860185)9 Ichikawa M. and Kurokawa M. (2009)
    658. Haematological & molecular profile of acute myelo genous leukaemia in India. (PubMed id 19491417)9 Sazawal S....Saxena R. (2009)
    659. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. (PubMed id 19047294)9 BA1chner T....Hiddemann W. (2009)
    660. High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia. (PubMed id 19643984)9 Tang R....Legrand O. (2009)
    661. IL-16 can synergize with early acting cytokines to expand ex vivo CD34+ isolated from cord blood. (PubMed id 19006448)9 Rofani C....Berardi A.C. (2009)
    662. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. (PubMed id 18337767)9 Steelman L.S....McCubrey J.A. (2008)
    663. In vitro clinical-grade generation of red blood cells from human umbilical cord blood CD34+ cells. (PubMed id 18673341)9 Baek E.J....Kim H.O. (2008)
    664. [Development of tyrosine kinase inhibitors for hematologic neoplasms. FLT3 and JAK2 as therapeutic targets] (PubMed id 18729264)9 Lipka D....Fischer T. (2008)
    665. Genetic abnormalities in acute myelogenous leukemia w ith normal cytogenetics. (PubMed id 20425451)9 Wald D....Tse W. (2008)
    666. Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia. (PubMed id 18692686)9 Baldus C.D. and Bullinger L. (2008)
    667. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors. (PubMed id 18362070)9 Gracias V....Djuric S.W. (2008)
    668. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. (PubMed id 18308931)9 Garzon R....Falini B. (2008)
    669. [Therapy of acute promyelocytic leukemia in Czechia: results and analysis of prognostic factors] (PubMed id 18780575)9 Schwarz J....CetkovskA1 P. (2008)
    670. A celecoxib derivative inhibits focal adhesion signaling and induces caspase-8-dependent apoptosis in human acute myeloid leukemia cells. (PubMed id 18398841)9 Casanova I....Mangues R. (2008)
    671. Inhibition of PDGFR tyrosine kinase activity by a series of novel N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides: a SAR study on the bioisosterism of pyrimidine and imidazole. (PubMed id 17983688)9 Mahboobi S....BAPhmer F.D. (2008)
    672. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. (PubMed id 18787411)9 Park M.A....Dent P. (2008)
    673. Developments in targeted therapy of advanced gastrointestinal stromal tumors. (PubMed id 18537751)9 Rutkowski P....Siedlecki J.A. (2008)
    674. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. (PubMed id 18209724)9 de Lima M....Shpall E.J. (2008)
    675. Antiangiogenic drugs and tyrosine kinases. (PubMed id 18537529)9 TA-mA!r J. and DAPme B. (2008)
    676. Generation of functional natural killer and dendritic cells in a human stromal-based serum-free culture system designed for cord blood expansion. (PubMed id 18155552)9 Frias A.M....Almeida-Porada G. (2008)
    677. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. (PubMed id 18288997)9 Petrelli A. and Giordano S. (2008)
    678. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies. (PubMed id 18177485)9 Matsumura I....Kanakura Y. (2008)
    679. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. (PubMed id 18701506)9 Case M....Irving J.A. (2008)
    680. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. (PubMed id 18373709)9 Al Shaer L....Rowntree C. (2008)
    681. HOX expression patterns identify a common signature for favorable AML. (PubMed id 18668134)9 Andreeff M....Drabkin H.A. (2008)
    682. Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15. (PubMed id 18295962)9 McCullar V....Miller J.S. (2008)
    683. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. (PubMed id 18192256)9 Hiles J.J. and Kolesar J.M. (2008)
    684. Ezrin is a target for oncogenic Kit mutants in murine erythroleukemia. (PubMed id 18182570)9 Monni R....Moreau-Gachelin F. (2008)
    685. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. (PubMed id 17505827)9 Britten C.D....Slamon D. (2008)
    686. Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date. (PubMed id 18345718)9 Brown P. and Smith F.O. (2008)
    687. In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. (PubMed id 18160102)9 Zhou J....Chen C.S. (2008)
    688. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia. (PubMed id 18388181)9 Jankovic D....Schwaller J. (2008)
    689. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. (PubMed id 18841055)9 Mrozek K....Bloomfield C.D. (2008)
    690. Clinically useful prognostic factors in acute myeloid leukemia. (PubMed id 17996460)9 Ferrara F....Leoni F. (2008)
    691. Prophylactic treatment with fms-like tyrosine kinase-3 ligand after burn injury enhances global immune responses to infection. (PubMed id 18292526)9 Bohannon J....Toliver-Kinsky T. (2008)
    692. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. (PubMed id 18692685)9 Gaidzik V. and DAPhner K. (2008)
    693. Ex vivo culture of human cord blood hematopoietic stem/progenitor cells adversely influences their distribution to other bone marrow compartments after intra-bone marrow transplantation. (PubMed id 17975223)9 Yamamura K....Katayama N. (2008)
    694. Small molecules ATP-competitive inhibitors of FLT3: a chemical overview. (PubMed id 19075657)9 Schenone S....Botta M. (2008)
    695. Sunitinib in the management of gastrointestinal stromal tumours (GISTs). (PubMed id 18082353)9 Hopkins T.G....Stark D. (2008)
    696. A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects. (PubMed id 19026036)9 Yin O.Q....Schran H. (2008)
    697. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. (PubMed id 17943167)9 Hatfield K.J....Bruserud O. (2008)
    698. FLT3 mutation and AML/ETO in a case of Myelodysplastic syndrome in transformation corroborates the two hit model of leukemogenesis. (PubMed id 17079011)9 Pinheiro R.F....Chauffaille M.d.e. .L. (2007)
    699. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. (PubMed id 17494858)9 Link D.C....Ley T.J. (2007)
    700. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. (PubMed id 17367763)9 Roskoski R. (2007)
    701. Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: possible application for cancer immunotherapy. (PubMed id 17487367)9 Harada S....Sonoda Y. (2007)
    702. Microenvironmental changes during differentiation of mesenchymal stem cells towards chondrocytes. (PubMed id 17391539)9 Djouad F....Jorgensen C. (2007)
    703. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. (PubMed id 17698633)9 Chase A....Cross N.C. (2007)
    704. Sunitinib: bridging present and future cancer treatment. (PubMed id 17591828)9 Grimaldi A.M....CartenA- G. (2007)
    705. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. (PubMed id 17541402)9 Pardanani A....Tefferi A. (2007)
    706. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. (PubMed id 17591826)9 Bracarda S....CrinA^ L. (2007)
    707. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor. (PubMed id 17588358)9 George S. (2007)
    708. [Abnormal activation of tyrosine kinases and its role in the pathogenesis of hematological malignancies - review] (PubMed id 17605888)9 Sun X.M. (2007)
    709. FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells. (PubMed id 17359372)9 Li L....Small D. (2007)
    710. Development of novel compounds to treat autoimmune and inflammatory diseases and graft versus host reactions. (PubMed id 17584149)9 Appel S. and Brossart P. (2007)
    711. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. (PubMed id 17803937)9 Chen H....Mohammadi M. (2007)
    712. TGF-beta combined with M-CSF and IL-4 induces generation of immune inhibitory cord blood dendritic cells capable of enhancing cytokine-induced ex vivo expansion of myeloid progenitors. (PubMed id 17585053)9 Li G....Broxmeyer H.E. (2007)
    713. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer. (PubMed id 17676584)9 El Fitori J....Friess H. (2007)
    714. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents. (PubMed id 17942916)9 Furuichi Y....Sugita K. (2007)
    715. Sunitinib: from rational design to clinical efficacy. (PubMed id 17327610)9 Chow L.Q. and Eckhardt S.G. (2007)
    716. Thrombopoietin enhances generation of CD34+ cells from human embryonic stem cells. (PubMed id 17379761)9 Srivastava A.S....Carrier E. (2007)
    717. A complex karyotype, including a three-way translocation generating a NUP98-HOXD13 transcript, in an infant with acute myeloid leukemia. (PubMed id 17656257)9 Hidaka E....Koike K. (2007)
    718. [Prevalence of FLT3 internal tandem duplication in adult acute myelogenous leukemia] (PubMed id 18094582)9 Lee J.N....Joo Y.D. (2007)
    719. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. (PubMed id 17488484)9 Baldus C.D....Bloomfield C.D. (2007)
    720. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations. (PubMed id 17671144)9 Kiyoi H....Naoe T. (2007)
    721. Dual treatment with FLT3 inhibitor SU11657 and doxoru bicin increases survival of leukemic mice. (PubMed id 17184839)9 Lee B.D....Kogan S.C. (2007)
    722. Notch ligand Delta-1 differentially modulates the effects of gp130 activation on interleukin-6 receptor alpha-positive and -negative human hematopoietic progenitors. (PubMed id 17645774)9 Yamamura K....Nakahata T. (2007)
    723. Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: interleukin-2 receptor alpha-chain predicts a poor prognosis. (PubMed id 17205058)9 Nakase K....Katayama N. (2007)
    724. [Molecular diagnosis of chronic myeloproliferative di seases and myelodysplastic syndromes] (PubMed id 18314608)9 Bock O. (2007)
    725. Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. (PubMed id 17210255)9 Mahboobi S....Dove S. (2007)
    726. Expansion and differentiation of CD14+CD16(-) and CD14+ +CD16+ human monocyte subsets from cord blood CD34+ hematopoietic progenitors. (PubMed id 17595380)9 Stec M....Zembala M. (2007)
    727. Sunitinib malate. (PubMed id 17136543)9 Izzedine H....Deray G. (2007)
    728. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. (PubMed id 17377585)9 Metzgeroth G....Reiter A. (2007)
    729. Exploiting signal transduction pathways in acute myelogenous leukemia. (PubMed id 18097642)9 Perl A.E. and Carroll M. (2007)
    730. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? (PubMed id 16960150)9 MrA^zek K....Bloomfield C.D. (2007)
    731. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. (PubMed id 17255787)9 MrA^zek K....Bloomfield C.D. (2007)
    732. Cloning and sequencing of ovine Flt3 ligand. (PubMed id 17504506)9 Chan S.S....Blacklaws B.A. (2007)
    733. [Acute myeloid leukemia] (PubMed id 18079616)9 Ohtake S. (2007)
    734. Impact of FLT3 internal tandem duplications on Indian acute promyelocytic leukemia patients: prognostic implications. (PubMed id 17454189)9 Hasan S.K....Saxena R. (2007)
    735. Candidate genes for expansion and transformation of hematopoietic stem cells by NUP98-HOX fusion genes. (PubMed id 17712416)9 Palmqvist L....Humphries R.K. (2007)
    736. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. (PubMed id 17658267)9 Doepfner K.T....Arcaro A. (2007)
    737. Murine dendritic cell transdifferentiation into osteoclasts is differentially regulated by innate and adaptive cytokines. (PubMed id 17304626)9 Speziani C....Delprat C. (2007)
    738. AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells. (PubMed id 17330097)9 Griessinger E....Peyron J.F. (2007)
    739. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. (PubMed id 19089671)9 LaRocca R.V....Foreman B. (2007)
    740. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. (PubMed id 17178882)9 Liu L....Carter C. (2006)
    741. Regeneration of megakaryocytopoiesis and thrombopoiesis in vitro from X-irradiated human hematopoietic stem cells. (PubMed id 16881735)9 Kashiwakura I....Kuwabara M. (2006)
    742. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. (PubMed id 16938665)9 Lin P....Luthra R. (2006)
    743. Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. (PubMed id 16557242)9 Hong Y....Erusalimsky J.D. (2006)
    744. Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. (PubMed id 16594743)9 Dunphy C.H. (2006)
    745. Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416. (PubMed id 17169805)9 Loges S....Fiedler W. (2006)
    746. Highly efficient ex vivo expansion of human hematopoietic stem cells using Delta1-Fc chimeric protein. (PubMed id 16857897)9 Suzuki T....Chiba S. (2006)
    747. Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with flt3 mutational status. (PubMed id 16270043)9 Marasca R....Torelli G. (2006)
    748. Acute myeloid leukemia subgroups identified by pathway-restricted gene expression signatures. (PubMed id 16914901)9 Serrano E....Nomdedeu J.F. (2006)
    749. Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation. (PubMed id 16557239)9 Suzuki M....Naoe T. (2006)
    750. The expansion of megakaryocyte progenitors from CD34+-enriched mobilized peripheral blood stem cells is inhibited by Flt3-L. (PubMed id 16487027)9 Case J....Manoharan A. (2006)
    751. JAK2 V617F in myeloid disorders: what do we know now, and where are we headed? (PubMed id 16321848)9 Nelson M.E. and Steensma D.P. (2006)
    752. NUP98-HOXA9 induces long-term proliferation and blocks differentiation of primary human CD34+ hematopoietic cells. (PubMed id 16818636)9 Takeda A....Yaseen N.R. (2006)
    753. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. (PubMed id 16598306)9 Steensma D.P....Kaufmann S.H. (2006)
    754. Microarrays for the functional analysis of the chemical-kinase interactome. (PubMed id 16314406)9 Horiuchi K.Y....Ma H. (2006)
    755. Constitutively activated FLT3 phosphorylates BAD partially through pim-1. (PubMed id 16869825)9 Kim K.T....Small D. (2006)
    756. Mutation of FLT3 is not a general phenomenon in CD117-positive T-ALL. (PubMed id 16081157)9 Scharnhorst V....van der Velden V.H. (2006)
    757. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. (PubMed id 16150941)9 Heidel F....Fischer T. (2006)
    758. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. (PubMed id 16291592)9 Shimada A....Hayashi Y. (2006)
    759. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. (PubMed id 16642045)9 Martelli A.M....Cocco L. (2006)
    760. Evaluation of CD34+ - and Lin- -selected cells from peripheral blood stem cell grafts of patients with lymphoma during differentiation in culture ex vivo using a cDNA microarray technique. (PubMed id 16797410)9 Koutna I....Mayer J. (2006)
    761. Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes. (PubMed id 17261784)9 Cilloni D....Saglio G. (2006)
    762. Establishment of a stroma-dependent human acute myelomonocytic leukemia cell line, NAMO-2, with FLT3 tandem duplication. (PubMed id 17118759)9 Abe A....Naoe T. (2006)
    763. The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment. (PubMed id 17124055)9 Lo-Coco F. and Ammatuna E. (2006)
    764. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. (PubMed id 16731761)9 Potapova O....Mendel D.B. (2006)
    765. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells. (PubMed id 16112192)9 Lu C. and Hassan H.T. (2006)
    766. Differentiation and maintenance of mast cells from CD34(+) human cord blood cells. (PubMed id 16543066)9 Yoshikubo T....Okabe H. (2006)
    767. Clinical implications of gene expression profiling of acute myeloid leukemia. (PubMed id 20425341)9 Mills K.I. and Gilkes A.F. (2006)
    768. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. (PubMed id 16418499)9 Baldus C.D....Ehninger G. (2006)
    769. Human CD34+ CD11b- cord blood stem cells generate in vitro a CD34- CD11b+ subset that is enriched in langerin+ Langerhans dendritic cell precursors. (PubMed id 17046566)9 Soulas C....Kindler V. (2006)
    770. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. (PubMed id 17172414)9 Zeng Z....Konopleva M. (2006)
    771. The investigation of mutation and single nucleotide polymorphism of receptor tyrosine kinases and downstream scaffold molecules in acute myeloid leukemia. (PubMed id 17169806)9 Zhang S.J....Li J.Y. (2006)
    772. Two consecutive immunophenotypic switches in a child with MLL-rearranged acute lymphoblastic leukemia. (PubMed id 16709517)9 Germano G....Basso G. (2006)
    773. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. (PubMed id 16585200)9 Zeng Z....Konopleva M. (2006)
    774. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. (PubMed id 16648571)9 Albert D.H....Davidsen S.K. (2006)
    775. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. (PubMed id 16467864)9 Niimi H....Kimura A. (2006)
    776. Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma. (PubMed id 16729906)9 Reddy G.K. and Bukowski R.M. (2006)
    777. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. (PubMed id 17041096)9 Ikezoe T....Taguchi H. (2006)
    778. Activation of the Flt3 signal transduction cascade rescues and enhances type I interferon-producing and dendritic cell development. (PubMed id 16418395)9 Onai N....Manz M.G. (2006)
    779. Clinical implications of FLT3 mutations in pediatric AML. (PubMed id 16912228)9 Meshinchi S....Radich J.P. (2006)
    780. Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors. (PubMed id 16399570)9 Leone F....Aglietta M. (2006)
    781. Chronic myelomonocytic leukemia evolving from preexis ting myelodysplasia shares many features with de novo disease. (PubMed id 17050076)9 Wang S.A....Raza A. (2006)
    782. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. (PubMed id 16446383)9 Radomska H.S....Tenen D.G. (2006)
    783. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. (PubMed id 16891463)9 Patyna S....Hu-Lowe D. (2006)
    784. Effect of hematopoietic growth factors on severity of experimental autoimmune encephalomyelitis. (PubMed id 16951693)9 Verda L....Burt R.K. (2006)
    785. [The diagnostic and predictive role of kit (CD117)] (PubMed id 16689459)9 Dirnhofer S....Went P. (2006)
    786. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. (PubMed id 16787503)9 Georgiou G....Panayiotidis P. (2006)
    787. A Stro-1(+) human universal stromal feeder layer to expand/maintain human bone marrow hematopoietic stem/progenitor cells in a serum-free culture system. (PubMed id 16982328)9 GonAsalves R....Almeida-Porada G. (2006)
    788. Identification of Flt3 internal tandem duplications downstream targets by high-throughput immunoblotting protein array system. (PubMed id 16838337)9 Takahashi S. (2006)
    789. Mutations of AML1 in non-M0 acute myeloid leukemia: six novel mutations and a high incidence of cooperative events in a South-east Asian population. (PubMed id 16627249)9 Auewarakul C.U....Tocharoentanaphol C. (2006)
    790. Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. (PubMed id 16849538)9 Camos M....Campo E. (2006)
    791. Molecular targeting therapy for renal cell carcinoma. (PubMed id 16850127)9 Eto M. and Naito S. (2006)
    792. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. (PubMed id 16275934)9 Marcucci G....Bloomfield C.D. (2005)
    793. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase. (PubMed id 15815726)9 Komeno Y....Hirai H. (2005)
    794. Soluble factors elaborated by human brain endothelial cells induce the concomitant expansion of purified human BM CD34+CD38- cells and SCID-repopulating cells. (PubMed id 15345596)9 Chute J.P....Oxford C. (2005)
    795. Bypass of senescence, immortalization, and transformation of human hematopoietic progenitor cells. (PubMed id 16144874)9 Akimov S.S....Hawley R.G. (2005)
    796. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. (PubMed id 16281072)9 Christiansen D.H....Pedersen-Bjergaard J. (2005)
    797. [Effect of anti-TGF-beta antibody on ex vivo expansion and expression of adhesion molecules of human cord blood CD34+ cells] (PubMed id 16129056)9 Qian J....Kang W.T. (2005)
    798. Somatic PTPN11 mutations in childhood acute myeloid leukaemia. (PubMed id 15842656)9 Tartaglia M....Biondi A. (2005)
    799. Sequencing of genomic DNA by combined amplification and cycle sequencing reaction. (PubMed id 15514094)9 Murphy K.M....Eshleman J.R. (2005)
    800. A human stromal-based serum-free culture system supports the ex vivo expansion/maintenance of bone marrow and cord blood hematopoietic stem/progenitor cells. (PubMed id 15963859)9 da Silva C.L....Almeida-Porada G. (2005)
    801. In vitro hematopoietic differentiation of human embryonic stem cells induced by co-culture with human bone marrow stromal cells and low dose cytokines. (PubMed id 15950498)9 Wang J....Lu G.X. (2005)
    802. [Acute monocytic leukemia after orthotopic liver transplantation: clinical features, molecular genetics, and significance thereof] (PubMed id 16686070)9 Zhang G.S....Yang J.J. (2005)
    803. Co-culture of human CD34+ cells with mesenchymal stem cells increases the survival of CD34+ cells against the 5-aza-deoxycytidine- or trichostatin A-induced cell death. (PubMed id 15752760)9 Koh S.H....Shin H.Y. (2005)
    804. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. (PubMed id 16076872)9 Gale R.E....Linch D.C. (2005)
    805. Preclinical ex vivo expansion of G-CSF-mobilized peripheral blood stem cells: effects of serum-free media, cytokine combinations and chemotherapy. (PubMed id 15654904)9 Li K....Yuen P.M. (2005)
    806. FLT3 mutations in childhood acute lymphoblastic leukemia at first relapse. (PubMed id 15674414)9 Wellmann S....Seeger K. (2005)
    807. Mesenchymal stem cells support expansion of in vitro irradiated CD34(+) cells in the presence of SCF, FLT3 ligand, TPO and IL3: potential application to autologous cell therapy in accidentally irradiated victims. (PubMed id 15966759)9 Mourcin F....Drouet M. (2005)
    808. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. (PubMed id 15718420)9 Grundler R....Duyster J. (2005)
    809. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. (PubMed id 15715049)9 Gyorffy S....Gauldie J. (2005)
    810. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. (PubMed id 16051734)9 Dohner K....Dohner H. (2005)
    811. Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3. (PubMed id 15667533)9 Smith M.L....Fitzgibbon J. (2005)
    812. Platelet-derived growth factor enhances expansion of umbilical cord blood CD34+ cells in contact with hematopoietic stroma. (PubMed id 15910249)9 Su R.J....Fok T.F. (2005)
    813. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. (PubMed id 16033847)9 Lopes de Menezes D.E....Heise C. (2005)
    814. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. (PubMed id 16304372)9 Tallman M.S. (2005)
    815. Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis? (PubMed id 15606546)9 Reilly J.T. (2005)
    816. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice. (PubMed id 15718357)9 BAockman U. and Christofferson R. (2005)
    817. FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia. (PubMed id 15982343)9 Torelli G.F....Foa R. (2005)
    818. Towards a pathogenesis-oriented therapy of acute myeloid leukemia. (PubMed id 16207531)9 Hiddemann W....BA1chner T. (2005)
    819. Targeted therapy in renal cell carcinoma. (PubMed id 16185167)9 Favaro J.P. and George D.J. (2005)
    820. Raf kinase as a target for anticancer therapeutics. (PubMed id 15827342)9 Sridhar S.S....Siu L.L. (2005)
    821. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. (PubMed id 16115922)9 Marzola P....Osculati F. (2005)
    822. Converging pathways in leukemogenesis and stem cell self-renewal. (PubMed id 15963848)9 Moore M.A. (2005)
    823. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. (PubMed id 15889156)9 Callens C....Dombret H. (2005)
    824. AF4p12, a human homologue to the furry gene of Drosophila, as a novel MLL fusion partner. (PubMed id 16061630)9 Hayette S.... Rimokh R. (2005)
    825. Cytokine-based treatment of accidentally irradiated victims and new approaches. (PubMed id 16219528)9 HAcrodin F. and Drouet M. (2005)
    826. Antigen-specific IgG elicited in subjects with prostate cancer treated with flt3 ligand. (PubMed id 15838384)9 Dunphy E.J. and McNeel D.G. (2005)
    827. [Expansion of erythroid progenitors and CD34+ cells by umbilical cord blood mononuclear cells] (PubMed id 15972135)9 Zhang J.X. and Mao P. (2005)
    828. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl -x(L). (PubMed id 15626738)9 Bagrintseva K....Spiekermann K. (2005)
    829. Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha(CXCL12)/CXCR4 axis. (PubMed id 15618475)9 Fukuda S....Pelus L.M. (2005)
    830. Mammalian target of rapamycin as a therapeutic target in leukemia. (PubMed id 16305491)9 Giles F.J. and Albitar M. (2005)
    831. Resistance to tyrosine kinase inhibitors: calling on extra forces. (PubMed id 15869901)9 Cools J....Marynen P. (2005)
    832. FLT3 mutations in normal karyotype acute myeloid leuk emia in first complete remission treated with autologous peripheral blood stem cell transplantation. (PubMed id 16184177)9 Yoshimoto G....Harada M. (2005)
    833. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. (PubMed id 15994285)9 Suzuki T....Naoe T. (2005)
    834. Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. (PubMed id 16272221)9 Whartenby K.A....Small D. (2005)
    835. Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia. (PubMed id 15390271)9 Gratias E.J....Emanuel P.D. (2005)
    836. Immunophenotype of hematopoietic stem cells from placental/umbilical cord blood after culture. (PubMed id 16302092)9 Pranke P....Visser J. (2005)
    837. A phase 1 study of SU11248 in the treatment of patien ts with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. (PubMed id 15459012)9 Fiedler W....Hossfeld D.K. (2005)
    838. Drug therapy for acute myeloid leukemia. (PubMed id 15870183)9 Tallman M.S....Rowe J.M. (2005)
    839. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. (PubMed id 15843821)9 Schlenk R.F....DAPhner H. (2005)
    840. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. (PubMed id 16109776)9 Verhaak R.G....Valk P.J. (2005)
    841. Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling. (PubMed id 16281935)9 Olesen L.H....Hokland P. (2005)
    842. Genetics of myeloid malignancies: pathogenetic and clinical implications. (PubMed id 16155011)9 FrAPhling S....Levine R.L. (2005)
    843. Identification of the adult human hemangioblast. (PubMed id 15186719)9 Loges S....Gehling U.M. (2004)
    844. Hox expression in AML identifies a distinct subset of patients with intermediate cytogenetics. (PubMed id 15085154)9 Roche J....Drabkin H.A. (2004)
    845. Thrombopoietin, flt3-ligand and c-kit-ligand modulate HOX gene expression in expanding cord blood CD133 cells. (PubMed id 15245565)9 McGuckin C.P....Thompson A. (2004)
    846. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. (PubMed id 15329908)9 Shih L.Y....Huang C.F. (2004)
    847. Are interleukin-16 and thrombopoietin new tools for the in vitro generation of dendritic cells? (PubMed id 15304384)9 Della Bella S....Berardi A.C. (2004)
    848. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. (PubMed id 14732923)9 Side L.E....Shannon K.M. (2004)
    849. Relevance of pathologic classifications and diagnosis of acute myeloid leukemia to clinical trials and clinical practice. (PubMed id 15217206)9 Tallman M.S. (2004)
    850. Detection of minimal residual disease in acute myelogenous leukemia. (PubMed id 15179004)9 Raanani P. and Ben-Bassat I. (2004)
    851. Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML. (PubMed id 14654075)9 Zheng R....Small D. (2004)
    852. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. (PubMed id 15448036)9 Ahmad T. and Eisen T. (2004)
    853. Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. (PubMed id 14985702)9 Morimoto A.M....Cherrington J.M. (2004)
    854. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. (PubMed id 15374944)9 Cools J....Gilliland D.G. (2004)
    855. [Detection of FLT3 gene and FLT3/ITD gene mutation in chronic myeloid leukemia and its significance] (PubMed id 15473940)9 Xu B....Zhou S.Y. (2004)
    856. Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid progenitor cell proliferation and differentiation in vitro. (PubMed id 14725899)9 Lewis J.L....Gordon M.Y. (2004)
    857. Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine. (PubMed id 16146887)9 Peled T....Nagler A. (2004)
    858. Transcriptional control of early B cell development. (PubMed id 15032574)9 Busslinger M. (2004)
    859. Expression of HOX genes in acute leukemia cell lines with and without MLL translocations. (PubMed id 15160920)9 Quentmeier H....Drexler H.G. (2004)
    860. In vitro generation of functional dendritic cells fro m human umbilical cord blood CD34+ cells by a 2-step culture method. (PubMed id 15540905)9 Ryu K.H....Shin H.Y. (2004)
    861. Umbilical cord blood stem cells can expand hematopoietic and neuroglial progenitors in vitro. (PubMed id 15093735)9 McGuckin C.P....Pettengell R. (2004)
    862. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. (PubMed id 15466206)9 Wilhelm S.M....Trail P.A. (2004)
    863. Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. (PubMed id 15543237)9 Vey N....Bertucci F. (2004)
    864. Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. (PubMed id 15362364)9 Oyarzo M.P....Medeiros L.J. (2004)
    865. [Study on the expression of hematopoietic growth factor gene in human umbilical vein endothelial cells using gene chip.] (PubMed id 15498125)9 Zhong Z.D....Huang S. (2004)
    866. Factors affecting retrovirus-mediated gene transfer to human CD34+ cells. (PubMed id 15241779)9 Hong Y....Kim S. (2004)
    867. Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trials. (PubMed id 15000426)9 Sistla A....Shenoy N. (2004)
    868. Isolation and characterization of pediatric canine bo ne marrow CD34+ cells. (PubMed id 15261691)9 Suter S.E....Henthorn P.S. (2004)
    869. Cytokine requirements differ for stroma and embryoid body-mediated hematopoiesis from human embryonic stem cells. (PubMed id 15504555)9 Tian X....Kaufman D.S. (2004)
    870. Differential expansion of umbilical cord blood mononuclear cell-derived natural killer cells dependent on the dose of interleukin-15 with Flt3L. (PubMed id 15102482)9 Nagamura-Inoue T....Takahashi T.A. (2004)
    871. [Preliminary study on extensive amplification of human dendritic cells differentiated from cord blood CD34+ progenitor cells by two-step culture] (PubMed id 14990042)9 Wang Y.F....Qiu L.G. (2004)
    872. FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. (PubMed id 15010072)9 Brown P. and Small D. (2004)
    873. Granule protein changes and membrane receptor phenotype in maturing human eosinophils cultured from CD34+ progenitors. (PubMed id 12752593)9 Al-Rabia M.W....Walsh G.M. (2003)
    874. A comparison of ex vivo expanded DCs derived from cord blood and mobilized adult peripheral blood plastic-adherent mononuclear cells: decreased alloreactivity of cord blood DCs. (PubMed id 14578097)9 Bracho F....Cairo M.S. (2003)
    875. Control of hematopoietic stem/progenitor cell fate by transforming growth factor-beta. (PubMed id 12725536)9 Fortunel N.O....Hatzfeld A. (2003)
    876. FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. (PubMed id 12791658)9 Libura M....Macintyre E. (2003)
    877. Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells. (PubMed id 12637322)9 Kalberer C.P....Wodnar-Filipowicz A. (2003)
    878. Proliferation of human progenitor cells in a long-term culture system is more efficiently sustained by the addition of Flt-3 ligand or megakaryocyte growth and development factor than by Kit ligand. (PubMed id 12627848)9 Cartron G....Domenech J. (2003)
    879. Towards determining the differentiation program of antigen-presenting dendritic cells by transcriptional profiling. (PubMed id 12647933)9 Ju X.S....Martin Z. (2003)
    880. Adherent cells generated during long-term culture of human umbilical cord blood CD34+ cells have characteristics of endothelial cells and beneficial effect on cord blood ex vivo expansion. (PubMed id 12634419)9 Yoo E.S....Seong C.M. (2003)
    881. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. (PubMed id 12529667)9 Jilani I....Albitar M. (2003)
    882. Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies. (PubMed id 12483109)9 Clark J.J....Arceci R.J. (2003)
    883. Modelling of ex vivo expansion/maintenance of hematopoietic stem cells. (PubMed id 13680337)9 da Silva C.L....Cabral J.M. (2003)
    884. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with 'standard of care' therapeutic agents for the treatment of breast cancer. (PubMed id 14578466)9 Abrams T.J....Pryer N.K. (2003)
    885. Modulation of antitumor immune responses by hematopoietic cytokines. (PubMed id 12655538)9 Waller E.K. and Ernstoff M.S. (2003)
    886. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. (PubMed id 12966161)9 Moss K.G....Laird A.D. (2003)
    887. FLT3: ITDoes matter in leukemia. (PubMed id 12970773)9 Levis M. and Small D. (2003)
    888. Immunophenotyping as a guide for targeted therapy. (PubMed id 14592647)9 Sonneveld P. and Pieters R. (2003)
    889. [Oncogenes and leukemia: history and perspectives] (PubMed id 12836614)9 Gisselbrecht S. (2003)
    890. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. (PubMed id 12855656)9 London C.A....Cherrington J.M. (2003)
    891. The impact of progenitor enrichment, serum, and cytokines on the ex vivo expansion of mobilized peripheral blood stem cells: a controlled trial. (PubMed id 12529549)9 Balducci E....Vinante O. (2003)
    892. Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements. (PubMed id 12941810)9 Tsutsumi S....Hayashi Y. (2003)
    893. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. (PubMed id 12759922)9 Steudel C....Thiede C. (2003)
    894. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). (PubMed id 12468427)9 Guan Y....Hogge D.E. (2003)
    895. Cytokine expansion culture of cord blood CD34+ cells induces marked and sustained changes in adhesion receptor and CXCR4 expressions. (PubMed id 12529552)9 Denning-Kendall P....Hows J. (2003)
    896. A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. (PubMed id 12435730)9 BAPhmer F.D....Dove S. (2003)
    897. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. (PubMed id 12663439)9 Grundler R....Duyster J. (2003)
    898. Resistance to spontaneous apoptosis in acute myeloid leukaemia blasts is associated with p-glycoprotein expression and function, but not with the presence of FLT3 internal tandem duplications. (PubMed id 12648071)9 Pallis M....Russell N. (2003)
    899. Detection of FLT3 internal tandem duplication and D83 5 mutations by a multiplex polymerase chain reaction and capillary electrophore sis assay. (PubMed id 12707374)9 Murphy K.M....Berg K.D. (2003)
    900. Red marrow radiation dose adjustment using plasma FLT 3-L cytokine levels: improved correlations between hematologic toxicity and bon e marrow dose for radioimmunotherapy patients. (PubMed id 12515878)9 Siegel J.A....Blumenthal R.D. (2003)
    901. Macrophage colony-stimulating factor in cooperation w ith transforming growth factor-beta1 induces the differentiation of CD34+ hemat opoietic progenitor cells into Langerhans cells under serum-free conditions wit hout granulocyte-macrophage colony-stimulating factor. (PubMed id 12542531)9 Mollah Z.U....Tagami H. (2003)
    902. Flt3 mutations and leukaemia. (PubMed id 12899708)9 Kottaridis P.D....Linch D.C. (2003)
    903. Development and functions of natural killer cells. (PubMed id 12894844)9 Shibuya A. (2003)
    904. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. (PubMed id 12649163)9 Giles F.J....Karp J.E. (2003)
    905. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. (PubMed id 12843001)9 Fiedler W....Berdel W.E. (2003)
    906. Oncogenic receptor tyrosine kinase in leukemia. (PubMed id 14656048)9 Mizuki M....Kanakura Y. (2003)
    907. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. (PubMed id 12702504)9 Meshinchi S....Radich J.P. (2003)
    908. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. (PubMed id 12551822)9 Moreno I....Sanz M.A. (2003)
    909. Normal human bone marrow CD34(+)CD133(+) cells contain primitive cells able to produce different categories of colony-forming unit megakaryocytes in vitro. (PubMed id 12225797)9 Charrier S....Berger M.G. (2002)
    910. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. (PubMed id 11739689)9 Moore A.C....Nabel G.J. (2002)
    911. Flt3 ligand and conjugation to IL-1beta peptide as ad juvants for a type 1, T-cell response to an HIV p17 gag vaccine. (PubMed id 12009292)9 Pisarev V.M....Talmadge J.E. (2002)
    912. Proteolytic enzyme levels are increased during granulocyte colony-stimulating factor-induced hematopoietic stem cell mobilization in human donors but do not predict the number of mobilized stem cells. (PubMed id 12183836)9 van Os R....Fibbe W.E. (2002)
    913. Retroviral-mediated IL-12 gene transduction into human CD34+ cell-derived dendritic cells. (PubMed id 12168093)9 Akiyama Y....Yamaguchi K. (2002)
    914. Ex vivo expansion of stem and progenitor cells in co-culture of mobilized peripheral blood CD34+ cells on human endothelium transfected with adenovectors expressing thrombopoietin, c-kit ligand, and Flt-3 ligand. (PubMed id 11847009)9 Feugier P....Moore M.A. (2002)
    915. Platelet-derived growth factor promotes ex vivo expansion of CD34+ cells from human cord blood and enhances long-term culture-initiating cells, non-obese diabetic/severe combined immunodeficient repopulating cells and formation of adherent cells. (PubMed id 12028051)9 Su R.J....Yuen P.M. (2002)
    916. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. (PubMed id 12145694)9 Teller S....BAPhmer F.D. (2002)
    917. In vitro expansion of cord blood does not prevent engraftment of severe combined immunodeficient repopulating cells. (PubMed id 11841420)9 Denning-Kendall P.A....Hows J.M. (2002)
    918. Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. (PubMed id 12000870)9 Marroquin C.E....Hwu P. (2002)
    919. FLT3 in human hematologic malignancies. (PubMed id 12400596)9 Kiyoi H. and Naoe T. (2002)
    920. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. (PubMed id 12239157)9 Fukuda S....Pelus L.M. (2002)
    921. [Molecular mechanisms in leukemogenesis] (PubMed id 12145988)9 Mitani K. (2002)
    922. Human CD34+ hematopoietic stem/progenitor cells express high levels of FLIP and are resistant to Fas-mediated apoptosis. (PubMed id 11897874)9 Kim H....Civin C.I. (2002)
    923. Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. (PubMed id 12000869)9 Rini B.I....Stadler W.M. (2002)
    924. [CD40 ligandization promotes IL-6 and Flt3 ligand production of bone marrow stromal cells] (PubMed id 12482343)9 Fu J....Zhang X. (2002)
    925. Optimisation of transfection conditions of CD34+ hematopoietic cells derived from human umbilical cord blood. (PubMed id 12422232)9 OA8dak T....Pojda Z. (2002)
    926. Interaction of human hematopoietic stem cells with bacterial pathogens. (PubMed id 12393678)9 Kolb-MAourer A....Goebel W. (2002)
    927. Cloning and characterization of a proliferation-associated cytokine- inducible protein, CIP29. (PubMed id 11922608)9 Fukuda S.... Pelus L.M. (2002)
    928. Cellular copper content modulates differentiation and self-renewal in cultures of cord blood-derived CD34+ cells. (PubMed id 11849228)9 Peled T....Fibach E. (2002)
    929. Interleukin 8 and Flt3 ligand as markers of advanced disease in primary gastrointestinal non-Hodgkin's lymphoma. (PubMed id 11956621)9 Retzlaff S....Berdel W.E. (2002)
    930. Elevation of Survivin levels by hematopoietic growth factors occurs in quiescent CD34+ hematopoietic stem and progenitor cells before cell cycle entry. (PubMed id 12461294)9 Fukuda S. and Pelus L.M. (2002)
    931. Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line. (PubMed id 11840291)9 Srinivasa S.P. and Doshi P.D. (2002)
    932. Ex vivo treatment of proliferating human cord blood stem cells with stroma-derived factor-1 enhances their ability to engraft NOD/SCID mice. (PubMed id 11964317)9 Glimm H....Eaves C. (2002)
    933. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy. (PubMed id 12373354)9 Bojko P....Seeber S. (2002)
    934. Molecular genetics of human leukemias: new insights into therapy. (PubMed id 12447846)9 Gilliland D.G. (2002)
    935. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. (PubMed id 11756186)9 Kelly L.M....Gilliland D.G. (2002)
    936. Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used; and engraftment in NOD/SCID mice. (PubMed id 11778074)9 Lam A.C....Yuen P.M. (2001)
    937. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. (PubMed id 11567995)9 Fukuda S. and Pelus L.M. (2001)
    938. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. (PubMed id 11585760)9 Whitman S.P....Caligiuri M.A. (2001)
    939. Evaluation of the effect of cryopreservation on ex vivo expansion of hematopoietic progenitors from cord blood. (PubMed id 11704793)9 Lazzari L....Sirchia G. (2001)
    940. Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice. (PubMed id 11739152)9 Bjorck P. (2001)
    941. Persistent low-level engraftment of rhesus peripheral blood progenitor cells transduced with the fanconi anemia C gene after conditioning with low-dose irradiation. (PubMed id 11407905)9 Kang E.M....Tisdale J.F. (2001)
    942. Effects of lithium on thrombopoiesis in patients with low platelet cell counts following chemotherapy or radiotherapy. (PubMed id 11762531)9 Hager E.D....Strama H. (2001)
    943. Murine prolactin-like protein E synergizes with human thrombopoietin to stimulate expansion of human megakaryocytes and their precur sors. (PubMed id 11164105)9 Lefebvre P....Cohen I. (2001)
    944. Prior cryopreservation of ex vivo-expanded cord blood cells is not detrimental to engraftment as measured in the NOD-SCID mouse mode l. (PubMed id 11276369)9 Rice A.M....Vowels M.R. (2001)
    945. Optimization of culture conditions to enhance transfe ction of human CD34+ cells by electroporation. (PubMed id 11551032)9 Wu M.H....Dolan M.E. (2001)
    946. ARG tyrosine kinase activity is inhibited by STI571. (PubMed id 11290609)9 Okuda K....Griffin J.D. (2001)
    947. Platelet-derived growth factor enhances ex vivo expansion of megakaryocytic progenitors from human cord blood. (PubMed id 11438824)9 Su R.J....Yuen P.M. (2001)
    948. Comparison of different serum-free media for ex vivo expansion of HPCs from cord blood using thrombopoietin, Flt-3 ligand, IL-6, and IL-11. (PubMed id 11346712)9 Lazzari L....Sirchia G. (2001)
    949. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. (PubMed id 11427731)9 Fong L....Engleman E.G. (2001)
    950. Characterization of cytokine interactions by flow cytometry and factorial analysis. (PubMed id 11122486)9 Case J....Nordon R.E. (2001)
    951. Proliferative capacity of single isolated CD34+ hematopoietic stem/progenitor cells in paroxysmal nocturnal hemoglobinuria. (PubMed id 11530804)9 Han B....Zhang Z. (2001)
    952. Immortalized multipotential mesenchymal cells and the hematopoietic microenvironment. (PubMed id 11276366)9 Dormady S.P....Basch R.S. (2001)
    953. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L). (PubMed id 11399510)9 Bruserud O....Petersen H. (2001)
    954. Dissociation between stem cell phenotype and NOD/SCID repopulating activity in human peripheral blood CD34(+) cells after ex vivo expansion. (PubMed id 11750106)9 Danet G.H....Bonnet D.A. (2001)
    955. Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response. (PubMed id 11719454)9 Parajuli P....Talmadge J.E. (2001)
    956. Measurement of interleukin 3 and other hematopoietic cytokines, such as GM-CSF, G-CSF, M-CSF, erythropoietin, steel factor, and Flt-3 ligand. (PubMed id 18432817)9 Cooper S.H. and Broxmeyer H.E. (2001)
    957. Cell proliferation through forced engagement of c-Kit and Flt-3. (PubMed id 11369667)9 Otto K.G....Blau C.A. (2001)
    958. Efficient lentiviral transduction of primary human acute myelogenous and lymphoblastic leukemia cells. (PubMed id 11146564)9 Biagi E....Introna M. (2001)
    959. Simplified retroviral vector gcsap with murine stem cell virus long terminal repeat allows high and continued expression of enhanced green fluorescent protein by human hematopoietic progenitors engrafted in nonobese diabetic/severe combined immunodeficient mice. (PubMed id 11177540)9 Kaneko S....Nakauchi H. (2001)
    960. High efficiency electroporation of human umbilical cord blood CD34+ hematopoietic precursor cells. (PubMed id 11713340)9 Wu M.H....Dolan M.E. (2001)
    961. The FLT3 tyrosine kinase receptor inhibits neural ste m/progenitor cell proliferation and collaborates with NGF to promote neuronal s urvival. (PubMed id 11640895)9 Brazel C.Y....Levison S.W. (2001)
    962. Cell cycle activation of hematopoietic progenitor cells increases very late antigen-5-mediated adhesion to fibronectin. (PubMed id 11301192)9 Giet O....Gothot A. (2001)
    963. CD34(+) cord blood cells expressing cutaneous lymphocyte-associated antigen are enriched in granulocyte-macrophage progenitors and support extensive amplification of dendritic cell progenitors. (PubMed id 11495709)9 Arrighi J.F....Kindler V. (2001)
    964. gp130-stimulating designer cytokine Hyper-interleukin-6 synergizes with murine stroma for long-term survival of primitive human hematopoietic progenitor cells. (PubMed id 11438204)9 GAPtze K.S....Peschel C. (2001)
    965. Cord blood G(0) CD34+ cells have a thousand-fold higher capacity for generating progenitors in vitro than G(1) CD34+ cells. (PubMed id 11713342)9 Summers Y.J....Testa N.G. (2001)
    966. A secreted and LIF-mediated stromal cell-derived activity that promotes ex vivo expansion of human hematopoietic stem cells. (PubMed id 10706861)9 Shih C.C....Forman S.J. (2000)
    967. Functional involvement of E-cadherin in TGF-beta 1-induced cell cluster formation of in vitro developing human Langerhans-type dendritic cells. (PubMed id 10903741)9 Riedl E....Strobl H. (2000)
    968. FLT3 ligand gene expression and protein production in human colorectal cancer cell lines and clinical tumor specimens. (PubMed id 10738251)9 Spagnoli G.C....Heberer M. (2000)
    969. In vitro and in vivo evidence for the long-term multilineage (myeloid, B, NK, and T) reconstitution capacity of ex vivo expanded human CD34(+) cord blood cells. (PubMed id 11146169)9 Kobari L....Douay L. (2000)
    970. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. (PubMed id 10991971)9 Buchdunger E....Lydon N.B. (2000)
    971. Polyomavirus-infected dendritic cells induce antiviral CD8(+) T lymphocytes. (PubMed id 10756021)9 Drake D.R....Lukacher A.E. (2000)
    972. Ex vivo expansion of CD34+/CD41+ late progenitors from enriched peripheral blood CD34+ cells. (PubMed id 10663616)9 Halle P....DemAcocq F. (2000)
    973. Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia. Japan Infant Leukemia Study Group. (PubMed id 10803532)9 Xu F....Hayashi Y. (2000)
    974. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. (PubMed id 11021752)9 Tse K.F....Small D. (2000)
    975. High-efficiency retroviral transduction of mammalian cells on positively charged surfaces. (PubMed id 10646638)9 Hennemann B....Eaves C.J. (2000)
    976. Effect of ex vivo cytokine treatment on human cord blood engraftment in NOD-scid mice. (PubMed id 10759723)9 Ballen K....Quesenberry P. (2000)
    977. Effects of flt-3 ligand in combination with TPO on the expansion of megakaryocytic progenitors. (PubMed id 10784074)9 Li K....Yuen P.M. (2000)
    978. Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells. (PubMed id 10720135)9 Boyer M.W....Yeager A.M. (2000)
    979. Characterization of dendritic cell differentiation pathways from cord blood CD34(+)CD7(+)CD45RA(+) hematopoietic progenitor cells. (PubMed id 11090056)9 Canque B....Gluckman J.C. (2000)
    980. Ex vivo expansion of megakaryocytic cells. (PubMed id 10846824)9 Maurer A.M....Han Z.C. (2000)
    981. Circulating hematopoietic progenitor cells in first trimester fetal blood. (PubMed id 10706862)9 Campagnoli C....Roberts I. (2000)
    982. MDR1 gene expression in NOD/SCID repopulating cells after retroviral gene transfer under clinically relevant conditions. (PubMed id 11124062)9 Schilz A.J....Eckert H.G. (2000)
    983. Preincubation with endothelial cell monolayers increases gene transfer efficiency into human bone marrow CD34(+)CD38(-) progenitor cells. (PubMed id 11119422)9 Chute J.P....Kaushal S. (2000)
    984. Evidence that ceramide mediates the ability of tumor necrosis factor to modulate primitive human hematopoietic cell fates. (PubMed id 11110682)9 Maguer-Satta V....Eaves C.J. (2000)
    985. Antileukemic activity of Flt3 ligand in murine leukem ia. (PubMed id 10766177)9 Wang A....Cornetta K. (2000)
    986. Structure of the active core of human stem cell factor and analysis of binding to its receptor kit. (PubMed id 10880433)9 Jiang X....Hendrickson W.A. (2000)
    987. Radiation sensitivity of megakaryocyte colony-forming cells in human placental and umbilical cord blood. (PubMed id 10629613)9 Kashiwakura I....Takagi Y. (2000)
    988. A defined window for efficient gene marking of severe combined immunodeficient-repopulating cells using a gibbon ape leukemia virus-pseudotyped retroviral vector. (PubMed id 10646642)9 Demaison C....Thrasher A.J. (2000)
    989. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. (PubMed id 11099317)9 Morse M.A....Lyerly H.K. (2000)
    990. Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice. (PubMed id 10666196)9 Schiedlmeier B....Fruehauf S. (2000)
    991. Dendritic cell biology and the application of dendrit ic cells to immunotherapy of multiple myeloma. (PubMed id 10713654)9 HA!jek R. and Butch A.W. (2000)
    992. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. (PubMed id 10764154)9 Rombouts W.J....Ploemacher R.E. (2000)
    993. Flt3 ligand structure and unexpected commonalities of helical bundles and cystine knots. (PubMed id 10881197)9 Savvides S.N.... Karplus P.A. (2000)
    994. Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease. (PubMed id 10720156)9 Nakao M....Bartram C.R. (2000)
    995. Effective ex vivo generation of granulopoietic postprogenitor cells from mobilized peripheral blood CD34(+) cells. (PubMed id 10781904)9 Scheding S....Brugger W. (2000)
    996. Expansion of human cord blood CD34(+)CD38(-) cells in ex vivo culture during retroviral transduction without a corresponding increase in SCID repopulating cell (SRC) frequency: dissociation of SRC phenotype and function. (PubMed id 10607692)9 Dorrell C....Dick J.E. (2000)
    997. Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1. (PubMed id 10619866)9 Jo D.Y....Moore M.A. (2000)
    998. Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells. (PubMed id 10453005)9 Williams N.S....Kumar V. (1999)
    999. Rapid differentiation of a rare subset of adult human lin(-)CD34(-)CD38(-) cells stimulated by multiple growth factors in vitro. (PubMed id 10477721)9 Fujisaki T....Eaves C.J. (1999)
    1000. Ex vivo expansion of enriched CD34+ cells from neonatal blood in the presence of thrombopoietin, a comparison with cord blood and bone marrow. (PubMed id 10455361)9 Liu J....Li C.K. (1999)
    1001. CD34+ cells from mobilized peripheral blood retain fetal bone marrow repopulating capacity within the Thy-1+ subset following cell division ex vivo. (PubMed id 10378888)9 Young J.C....Hill B.L. (1999)
    1002. Early progenitor cells from human mobilized peripheral blood express low levels of the flt3 receptor, but exhibit various biological responses to flt3-L. (PubMed id 10460591)9 Aurran-Schleinitz T....Chabannon C. (1999)
    1003. The reduction of in vitro radiation-induced Fas-related apoptosis in CD34+ progenitor cells by SCF, FLT-3 ligand, TPO, and IL-3 in combination resulted in CD34+ cell proliferation and differentiation. (PubMed id 10527462)9 Drouet M....Herodin F. (1999)
    1004. Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes. (PubMed id 10697556)9 Allampallam K....Raza A. (1999)
    1005. The potential of human mast cell progenitors to differentiate into mature mast cells remains after prolonged culture with flt3 ligand, interleukin-3 or granulocyte-macrophage colony stimulating factor. (PubMed id 10086789)9 Hjertson M....Nilsson G. (1999)
    1006. Interleukin-11 (IL-11) enhances clonal proliferation of acute myelogenous leukemia cells with strong expression of the IL-11 receptor alpha chain and signal transducing gp130. (PubMed id 10400417)9 Kimura T....Sonoda Y. (1999)
    1007. Umbilical cord blood from preterm human fetuses is rich in committed and primitive hematopoietic progenitors with high proliferative and self-renewal capacity. (PubMed id 10428511)9 Wyrsch A....Wodnar-Filipowicz A. (1999)
    1008. Ex-Vivo Expansion of CFU-GM and BFU-E in Unselected PBMC Cultures with Flt3L is Enhanced by Autologous Plasma. (PubMed id 12881174)9 Guo M....Winter J.N. (1999)
    1009. [Immunohistochemical detection of cytokine receptors on cryostat tissue sections] (PubMed id 10379062)9 Kumberova A....Kolarova M. (1999)
    1010. Human neonatal blood: stem cell content, kinetics of CD34+ cell decline and ex vivo expansion capacity. (PubMed id 10027731)9 Li K....Yuen P.M. (1999)
    1011. A comparative study of the cell cycle status and primitive cell adhesion molecule profile of human CD34+ cells cultured in stroma-free versus porcine microvascular endothelial cell cultures. (PubMed id 10029177)9 Chute J.P....Davis T.A. (1999)

    (in PubMed, OMIM, and NCBI Bookshelf)
    About This Section
    Free Text  

      Query String
    NCBI Bookshelf
      (Note: In FireFox, select the above section and copy using Ctrl-C)

    (According to Entrez Gene, HGNC, AceView, euGenes, Ensembl, miRBase, ECgene, Kegg, and/or H-InvDB)
    About This Section
    Entrez Gene: 2322 HGNC: 3765 AceView: FLT3 Ensembl:ENSG00000122025 euGenes: HUgn2322
    ECgene: FLT3 Kegg: 2322 H-InvDB: FLT3

    (According to HUGE)
    About This Section

    (According to PharmGKB, ATLAS, HORDE, IMGT, LEIDEN, UniProtKB/Swiss-Prot, and/or UniProtKB/TrEMBL,
    Wikipedia and/or GeneReviews via UniProtKB/Swiss-Prot)
    About This Section
    PharmGKB entry for FLT3 Pharmacogenomics, SNPs, Pathways
    ATLAS Chromosomes in Cancer entry for FLT3 Genetics and Cytogenetics in Oncology and Haematology

    (Patent information from GeneIP,
    Licensable technologies from WIS Yeda, Salk, Tufts,
    IP news from LifeMap Sciences, Inc.)
    About This Section
    Patent Information for FLT3 gene:
    Search GeneIP for patents involving FLT3

    GeneCards and IP:
    Japan Patent Office Licenses GeneCards     European Patent Office Licenses GeneCards     Improving the IP Search

    (Antibodies, recombinant proteins, and assays from EMD Millipore, R&D Systems, OriGene, QIAGEN, GenScript, Cell Signaling Technology, SABiosciences, Novus Biologicals, Sino Biological, Enzo Life Sciences, Abcam, ProSpec, Cloud-Clone Corp., Thermo Fisher Scientific, LSBio, Gene Editing from DNA2.0 and Sirion Biotech, Clones from EMD Millipore, OriGene, GenScript, Sino Biological, DNA2.0, SwitchGear Genomics, Vector BioLabs, Sirion Biotech, Cell lines from GenScript, and LifeMap BioReagents, PCR Arrays from SABiosciences, Drugs and/or compounds from EMD Millipore, Tocris Bioscience, and/or Enzo Life Sciences, In Situ Hybridization Assays from
    Advanced Cell Diagnostics, Animal models from inGenious Targeting Laboratory, genOway)
    About This Section

     EMD Millipore small molecules (inhibitor) for FLT3
     Browse for Gene Knock-down Tools from EMD Millipore
     EMD Millipore Purified and/or Recombinant FLT3 Protein
     Browse Kits and Assays available from EMD Millipore
     EMD Millipore Mono- and Polyclonal Antibodies for the study of FLT3
     Browse Clones for the Expression of Recombinant Proteins Available from EMD Millipore
     EMD Millipore Custom Antibody & Bulk Services
     EMD Millipore Preclinical / Clinical Development Services
     EMD Millipore Immunoassay Services
     EMD Millipore Target Screening & Profiling Services

     Antibodies for FLT3 (Flt-3/Flk-2)   Browse Cell Culture Products  
     ELISAs for FLT3 (Flt-3/Flk-2)   Browse Flow Cytometry Kits  
     Browse Primer Pairs   Browse Kinase Activity Assays/Reagents  
     Browse ELISpot Kits/Development Modules   Browse TFB/Immunoprecipitation Assays  
     Browse Apoptosis Detection Kits/Reagents   Browse Ubiquitin Proteasome Pathway (UPP) Assay Kits/Reagents  
     Browse DNA Damage/Repair Kits/Reagents   Browse Multiplex/Array Assay Kits/Reagents  
     Browse Cell Selection/Detection Kits/Reagents   Browse Secondary Antibodies/Controls/Staining Reagents  
     Browse Protease Activity Assays and Reagents   Recombinant/Natural Proteins for FLT3 (Flt-3/Flk-2)  
     Browse Stem Cell Products   Browse Tocris Biochemicals & Compounds  
     Browse cDNA Clones   Proteome Profiler Antibody Arrays for FLT3 (Flt-3/Flk-2)  
     OriGene Antibodies for FLT3   OriGene RNAi products in human, mouse, rat for FLT3  
     Browse OriGene qPCR primer pairs and template standards   OriGene Protein Over-expression Lysate for FLT3  
     OriGene MassSpec something-or-other for FLT3   OriGene clones in human, mouse for FLT3  
     OriGene qSTAR qPCR primer pairs in human, mouse for FLT3   OriGene Purified Protein for FLT3  
     OriGene ORF clones in mouse, rat for FLT3   OriGene custom cloning services - gene synthesis, subcloning, mutagenesis, variant library, vector shuttling  
     OriGene Custom Antibody Services for FLT3   OriGene Custom Protein Services for FLT3  

     QIAGEN Custom miScript Target Protector blocks miRNA-binding site of in human, mouse, rat FLT3
     QIAGEN SeqTarget long-range PCR primers for resequencing FLT3
     QIAGEN PyroMark CpG Assay predesigned Pyrosequencing DNA Methylation assays in human, mouse, rat FLT3
     QIAGEN FlexiTube/FlexiPlate siRNA for gene silencing in human, mouse, rat FLT3
     QIAGEN QuantiFast Probe-based Assays in human, mouse, rat FLT3
     QIAGEN QuantiTect SYBR Green Assays in human, mouse, rat FLT3
     GenScript Purified and Recombinant Proteins for FLT3 GenScript cDNA clones with any tag delivered in your preferred vector for FLT3
     GenScript FLT3-Activity-based Kinase Assay for Compound Screening GenScript Custom Superior Antibodies Services for FLT3
     GenScript Custom overexpressing Cell Line Services for FLT3 CloneReady with Over 120,000 Genes
     Gene Synthesis: Any Gene in Any Vector Vector-based siRNA and miRNA, Ready for Transfection
     Gene Mutant Library, Variants up to 10^11 Plasmid Preparation
     Custom Peptide Services
     Antibodies & Assays for FLT3 

     Regulatory tfbs in FLT3 promoter
     Search Chromatin IP Primers for FLT3
     RT2 qPCR Primer Assay in human, mouse, rat FLT3
     GNC Network for FLT3
     SABiosciences PCR Arrays including human, mouse, rat FLT3
     Tocris compounds for FLT3
     Proteins and Antibodies for FLT3
     Cell Lysates for FLT3
     cDNA Clones for FLT3
     4000+ Proteins
     Search Sino Biological for antibodies, proteins & pathways
     Protein Production Services
     Transfection Reagents
     Protein A/G/L resins
     Isotyping reagents
     Proteins for FLT3
     Search for proteins, assays, substrates, inhibitors & antibodies
     Novus Tissue Slides
     FLT3 antibodies
     FLT3 proteins
     FLT3 lysates
     Antibodies for FLT3
     See all of Abcam's Antibodies, Kits and Proteins for FLT3
     Custom Antibody / Protein Production Service
     Bulk Purchasing
     Advantages of Rabbit Monoclonal antibodies
     Abcam protocols and scientific support
     Browse ProSpec Recombinant Proteins

     Browse Proteins at Cloud-Clone Corp.
     Browse Antibodies at Cloud-Clone Corp.
     Browse ELISAs at Cloud-Clone Corp.
     Browse CLIAs at Cloud-Clone Corp.
     Search LifeMap BioReagents cell lines for FLT3
     Gene Synthesis
     Protein Engineering
     Variant Library Synthesis
     Codon Optimization
     Protein Production and Purification
     Advanced Cell Diagnostics RNAscope RNA in situ hybridization assays for FLT3
     SwitchGear 3'UTR luciferase reporter plasmids for FLT3
     SwitchGear Promoter luciferase reporter plasmids for FLT3
     ThermoFisher Antibody for FLT3
     Vector BioLabs ready-to-use adenovirus/AAV for human, mouse, rat FLT3
     inGenious Targeting Laboratory - Custom generated mouse model solutions for FLT3
     inGenious Targeting Laboratory - Custom generated inducible mouse model solutions for FLT3
     lentivirus for stable overexpression of FLT3
     lentivirus expression plasmids for stable overexpression of FLT3
     adenovirus for overexpression of FLT3
     LSBio Antibodies in human, mouse, rat for FLT3
    Customized transgenic rodents for:
     Biomarker expression
     Off-target effect monitoring
     Translational medicine
     Tissue-specific gene expresssion
     Time-controlled gene expresssion
    GeneCards Homepage - Last full update: 23 Oct 2013 - Incrementals: 4 Nov 2013 , 7 Nov 2013 , 23 Jan 2014

    View Random Gene

    (GIFtS: 73)
    transforming growth factor, beta 1
    GIFtS Group
    The GeneCards human gene database gene index: 1 3 5 6 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 

    Developed at the Crown Human Genome Center, Department of Molecular Genetics, the Weizmann Institute of Science

    Hot genes      Disease genes      FLT3 gene at Home site.
    hostname: index build: 106 solr: 1.4